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This project assessed the cost and cost-effectiveness of hypertension management in South 
Africa within the context of a text messaging-based intervention (StAR* study) conducted in 
an urban public-sector clinic in Cape Town. The StAR* study is a community randomized 
trial that investigated the effect of adherence support via short messaging service (SMS) on 
treatment adherence and patient outcomes for the management of hypertension at Vanguard 
CHC in Cape Town (Bobrow et al. 2016). Patients received behavioral text messages as 
reminders for them to collect and take their medication on time. The StAR* study, consisted 
of three arms that ran in parallel: participants in the control arm received unrelated messages; 
patients in the information-only arm received one-way information messages twice a week; 
and patients in the interactive arm received interactive SMS-texts at the same frequency as 
those in the information only arm (Bobrow et al. 2016). Patients in the interactive arm could 
respond to the messages and trigger a response from the healthcare provider. The text 
messaging based intervention was shown to improve hypertension outcomes over a 12-month 
period in hypertension patients by improving adherence and retention in care. The study 
showed, in the one-way intervention arm an improvement in adherence (measured by 
medication refill rates) and a small reduction in systolic blood pressure (2.2mm Hg reduction 
over 12months) (Bobrow et al. 2016).  
In this study, we assessed the cost and cost effectiveness of the StAR* intervention 
under routine care management at Vanguard CHC. We also assessed the cost of hypertension 
management from the health system perspective and the cost of accessing hypertension care 
from the patient perspective. A combination of the ingredients approach and step-down 
costing was used to cost hypertension care from a health system perspective while a 
questionnaire was administered to 250 patients to estimate patient costs. The primary 
outcomes were the average cost of hypertension care and the incremental cost of the text 
message-based adherence intervention (StAR* intervention), compared to usual care, per 
millimetre of mercury (mmHg) reduction in systolic blood pressure.  
Results of the study show that the average health system cost for hypertension 
management is R262 per visit and the patient cost of accessing hypertension care is R172 per 
visit.  The text messaging based intervention was found to have low implementation costs in 
this pilot phase. The monthly incremental cost of the text messaging based intervention cost 
iv 
 
was R4 per person. The incremental cost-effectiveness ratio of the intervention was R22 per 
mm Hg reduction.  
This study provides the first contemporary assessment of hypertension management 
costs and the cost-effectiveness of mobile-based hypertension adherence support in South 
Africa. Future work will seek to estimate the long-term cost-effectiveness of this intervention 
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Hypertension is the most common reason why South Africans visit health-care facilities 
(Eksteen, 2015; Mash et al., 2012). Many people are not aware that they have hypertension 
and this has led to the condition being regarded as a silent killer (Cappuccio & Capewell, 
2015). The overall hypertension prevalence rate in South Africa rose from 23.9% in 2001 to 
40% in 2010 among adults aged over 25 years (Day et al., 2014; Steyn et al., 1999). On its 
own, hypertension is the most common risk factor for cardiovascular diseases (CVDs) in 
South Africa (Eksteen, 2015; Day et al., 2014). Hypertension and its sequelae (i.e. CVDs) are 
associated with high costs for the health sector as well as loss of human capital owing to 
morbidity and premature mortality. The management of hypertension is expensive, and large 
investments are required to maintain the recommended blood-pressure level among affected 
individuals (Alcocer & Cueto, 2008).  
The effectiveness of hypertension management depends on patients taking their 
medication consistently, which usually requires taking tablets once to three times daily for the 
rest of their lives. Studies show that improving medication adherence increases the 
effectiveness of treatment and leads to better patient outcomes (Hamine et al., 2015; Kiselev 
et al., 2012). Improving adherence may also save costs by averting the development of CVDs 
in patients with hypertension. To monitor adherence and improve patient outcomes, mobile 
and wireless technologies (commonly abbreviated as mHealth) such as mobile phones are 
increasingly being used. Most studies to date examining the effectiveness of mHealth for a 
wide range of conditions have been carried out in high-income countries and have shown the 
positive effect on adherence of sending short message service (SMS) texts to patients as a 
reminder for them to take their medication on time (Anglada-Martinez et al., 2015). 
 
 




There is currently no research on the cost and cost-effectiveness of mHealth interventions for 
the management of hypertension in South Africa. This research is needed on the one hand to 
assess the feasibility and affordability of implementing these interventions, and on the other 
hand to compare mHealth interventions with alternative uses of resources through cost-
effectiveness studies. An example of a local study on mHealth interventions is the SMS-Text 
Adherence Support study (StAR* study), which this cost-effectiveness analysis forms part of. 
The StAR* study is described below. 
 
1.2 The SMS-Text Adherence Support study (StAR* study) 
 
In Cape Town, a community randomised trial (an SMS-text adherence support study), was 
conducted recently at Vanguard Community Health Centre (Vanguard CHC) in Bonteheuwel, 
South Africa, investigating the effects of adherence support via SMS texts on treatment 
adherence and patient outcomes in the management of hypertension (Bobrow et al., 2016; 
Leon et al., 2015; Bobrow et al., 2014). The StAR* study, conducted between June 2012 and 
August 2014, consisted of three arms that ran parallel to each other: patients in the control 
group received non-intervention messages; patients in the information-only arm received one-
way information messages twice a week; patients in the interactive arm received interactive 
SMS texts at the same frequency as those in the information-only arm (Bobrow et al., 2016; 
Leon et al., 2015; Bobrow et al., 2014). Patients in the interactive arm could respond to the 
messages and trigger a response from healthcare professionals. The study showed an 
improvement in adherence in terms of medicine collection and a small reduction in patients’ 
systolic blood pressure (Bobrow et al., 2016). 
 
1.3 Study Rationale 
 
The aim of this research is to assess the cost of different approaches to hypertension 
management within the context of the StAR* study. Only a few studies have examined the 
cost and cost-effectiveness of mHealth interventions (Larsen-Cooper et al., 2015; de la Torre-
Díez et al., 2015; Rodrigues et al., 2014; Zurovac et al., 2012; Parker et al., 2007), with no 
studies conducted to date on hypertension in South Africa. The information on cost and cost-
effectiveness can be used to assess the feasibility, affordability and implications of 
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implementing mHealth in hypertension management in a cost-effectiveness analysis. Using 
the StAR* trial, this study will therefore estimate retrospectively the cost and cost-
effectiveness of the mobile intervention in hypertension management from a societal 
perspective.  
2 Mini Literature Review 
 
2.1 Economic burden of Hypertension 
 
Most studies on the cost of hypertension have been conducted in middle- and high-income 
countries, with very few studies done in low-income countries. Appendix A shows a 
summary of some of the cost studies on hypertension care conducted to date. Based on the 
findings of these studies, hypertension management is costly, making it both a health and an 
economic burden. The cost of hypertension care varied from country to country, with the 
United States of America (USA) having the highest cost of care while Nigeria had the lowest 
cost of care. In the USA, annual direct expenditure of hypertension is as high as US$54.0 
billion (Balu & Thomas, 2006). High-income countries have the highest unit cost of care, 
followed firstly by middle-income countries, and lastly by low-income countries. Looking at 
Appendix A, the cost of care is highest in Canada, the USA and China. Nigeria, being the 
low-income country among them, has the lowest unit cost of care at US$9.6 per month 
(Ilesanmi, Ige & Adebiyi, 2013). 
Regardless of the unit cost of care, the economic impact of hypertension care is huge in 
all countries. The high cost of care for hypertension subjected many patients residing in the 
south-western part of China to catastrophic payments. 8.9% of the population experienced 
catastrophic payments and 4.1% of those households became impoverished after paying the 
hypertension costs (Le et al., 2012). In Nigeria, hypertension costs led to a 52.8% incidence 
of catastrophic payments among the study population (Ilesanmi, Ige & Adebiyi, 2013). A 
catastrophic payment occurs when a household uses more than 10% of its total household 
income on healthcare (in this case, hypertension costs). Impoverishment refers to the 
percentage of the population that drops below the poverty line after paying healthcare costs 
(Mills et al., 2012). In 2010, the annual costs of hypertension care in Brazil were so high that 
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the annual costs represented 0.08% of the country’s Gross Domestic Product (GDP) (Dib, 
Riera & Ferraz, 2010). Considering that the total healthcare expenditure as a percentage of 
GDP for Brazil was 7.6%, hypertension posed a very huge economic burden, as it accounted 
for merely 1.1% of that 7.6% in that year.    
Looking at the drivers of hypertension costs, the major drivers in most cases are anti-
hypertensive drugs (Nguyen et al., 2014; Le et al., 2012; Al-Efan, 2009), except when the 
study includes hospital care costs (Nguyen et al., 2014). In some instances, antihypertensive 
drugs were attributable to up to 80% of the total cost of hypertension care (Maetzel et al., 
2004). Also, as the number of antihypertensive drugs per patient increases, so does the cost of 
care (Al-Efan, 2009). Different regions use different first-line antihypertensive drugs for 
hypertension management. In most studies, diuretics are the first-line treatment (Ganiyu & 
Suleiman, 2014; Costa, Juvenal Soares Dias da et al., 2002), while in other countries, like 
Bulgaria and Serbia, the first-line drugs were angiotensin-converting-enzyme inhibitors (ACE 
inhibitors), followed by treatment with calcium-channel blockers (Ivanova et al., 2009). With 
different first-line drugs, the cost of hypertension care would differ, since the costs of the 
individual drugs would be different. Diuretics and the use of no more than 2 antihypertensive 
drugs per person were found to be cost-effective (Ganiyu & Suleiman, 2014; Costa, Juvenal 
Soares Dias da et al., 2002). In addition, the presence of co-morbidities and the severity of 
hypertension affect the cost of hypertension care. Co-morbidities have a significant influence 
on the total cost of hypertension management (Maetzel et al., 2004).  The cost of care for 
patients with advanced hypertension or for those with comorbid diseases is higher than for 
those with primary hypertension alone (Ilesanmi, Ige & Adebiyi, 2013). A study by Nguyen 
et al. (2014) indicated that the total cost of hypertension care on its own in Vietnam was 
lower than the total cost of hypertension care among individuals with both hypertension and 
hyperlipidaemia. 
 
2.2 Models of Care: mHealth 
    
To improve adherence in hypertension and its outcomes, new models of care are being 
implemented. Among other strategies, such as nurse- and pharmacist-led interventions, 
mHealth technologies have recently been introduced for the management of hypertension. 
mHealth is defined as the use of mobile phones to facilitate communication in the health 
sector (Adibi, 2015). MHealth has been used in managing chronic diseases like asthma, 
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obesity, hypertension and diabetes (Nundy et al., 2012). MHealth is increasingly being used 
in the healthcare sector, owing to the rapid advancements in mobile technologies and the 
availability of mobile phones within the population (Leon, Schneider & Daviaud, 2012). 
With mHealth, practitioners can communicate with patients on a larger scale instantaneously 
(Carter, Bosworth & Green, 2012), and socioeconomic barriers that often reduce access to 
care are reduced (Leon, Schneider & Daviaud, 2012). For example, in South Africa, the 
majority of the population, from the poor to the rich, owns a mobile phone (Leon, Schneider 
& Daviaud, 2012), meaning that the majority of the population can be reached using mobile 
phones, irrespective of social status. 
Randomised control trials have shown the benefits of the use of mHealth in diabetic 
patients with hypertension, in terms of controlling blood sugar and blood pressure (Fischer et 
al., 2012; Earle et al., 2010; Logan et al., 2007). Better blood-pressure control was also seen 
in patients making use of mHealth to monitor their hypertension (Logan et al., 2007). When 
people can see the changes in their blood-pressure readings over time, they are more likely to 
adhere to their medication in the future in order to achieve better outcomes (Logan et al., 
2007). mHealth, unlike other models of care for hypertension, provides a platform for 
engaging with patients throughout the treatment process, while offering real-time responses 
(Logan et al., 2007). It also allows for active patient engagement between providers and 
patients, which encourages self-management, increases health awareness and makes patients 
more accountable for their actions (Fischer et al., 2012). Simple and less complicated 
mHealth interventions such as the use of SMS texts were found to be more favourable among 
individuals (Logan, 2013).  
However, very few studies have been conducted on the cost and cost-effectiveness of 
mHealth in low- and middle-income countries, none of which were on hypertension or its 
associated NCDs (Larsen-Cooper et al., 2015; de la Torre-Díez et al., 2015; Rodrigues et al., 
2014; Zurovac et al., 2012; Parker et al., 2007). There is a gap in the research when it comes 
to the cost and cost-effectiveness of mHealth interventions in the management of 
hypertension. In South Africa, there are no studies to date that have assessed the cost of 
hypertension management. This study aims to assess the cost and cost-effectiveness of a 
mobile-based intervention in hypertension management. Based on a few studies that assessed 
the costs of using mHealth interventions in other diseases, the cost of setting up mHealth 
interventions and their system-development contributes a larger proportion of the total cost 
than do their running costs (Zurovac et al., 2012). Also, because the StAR* study mobile 
18 
intervention included some donated resources (i.e. free development of the SMS database), 
knowing the economic cost of intervention is of great importance. Other studies have shown 
that mHealth may present high costs in small-scale settings, yet when used on a larger scale 
may be inexpensive (Zurovac et al., 2012). In the next section, we look at the different 
methods that were used to conduct economic evaluations in mHealth. 
2.3 Methodological overview 
To measure the effectiveness of new technologies such as mHealth, four types of economic 
evaluations are commonly used. These include cost-effectiveness analysis (CEA), cost-utility 
analysis (CUA), cost-benefit analysis (CBA) and cost minimisation (CMA) (Drummond et al. 
2005). An economic evaluation is a systematic method used to compare two or more 
interventions in terms of their costs and consequences (Drummond et al. 2005, Acharya et al. 
2011). A cost-benefit analysis is used when the outcome(s) of interest is measured in 
monetary terms such that the costs and outcomes are in the same units. In a cost-benefit 
analysis, outcomes are converted into monetary terms using the Human Capital Approach 
(HCA) or the willingness-to-pay approach. The HCA measures the opportunity cost of an 
individual based on his or her income, while the willingness-to-pay approach simply assesses 
the maximum amount that individuals are willing to pay for a certain intervention. The 
preferred intervention when using the HCA method is the one in which the intervention’s 
benefits outweigh its costs.  
A cost-effectiveness analysis is used when the outcome(s) of interest is measured in its 
natural units, i.e., cost per blood-pressure reduction (in mmHg) (Drummond et al., 2005). 
Incremental cost-effectiveness ratios (ICERs) are used to determine the preferred 
intervention, rather than the intervention with the lower ICER. A cost-utility analysis captures 
both the quantity and quality of outcomes. The quality of life is measured as either a quality-
adjusted life year gained (QALY) or a disability-adjusted life year gained (DALY).  The later 
refers to the number of years lost because of illness, while the former refers to the quality of 
life years gained because of an intervention or program. In a cost minimisation, the 
interventions being compared both have the same effect in terms of outcomes, while their 
costs differ. The intervention with the lowest cost is used. 
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A cost analysis refers to the quantification and valuation of all the resources used in an 
intervention. CUA, CBA, CEA and CMA are considered full economic evaluations 
(Drummond). This study makes use of a cost analysis, which is considered a partial economic 
evaluation. However, because the other part of the study involves the comparison of the cost-
analysis results with the outcomes of the StAR* study in their natural units, the study is 
referred to as a cost-effectiveness analysis.  A full economic evaluation involves the 
comparison of both the inputs and the consequences of each intervention, whereas a cost 
analysis is the first part of an economic evaluation (Acharya et al., 2011). Unlike other 
economic evaluation methods, cost analysis does not involve the outcomes; hence, it is 
referred to as a partial economic analysis. Even though cost analysis is not considered a full 
economic-evaluation method, it is still considered an economic evaluation (Acharya et al., 
2011).  
 
2.4 Costing and costing perspectives 
 
Assessing the cost of care in a disease-specific cost study is dependent on the costing 
methodology used, the type of study conducted and the perspective that is taken in the study.  
Appendix A shows a summary of the costing studies as well as their perspectives. Many of 
the studies were cross-sectional studies – cross-sectional in the sense that data analysis for a 
certain population or subgroup was done at a specific point in time. Different perspectives 
(patient, provider and societal) were taken to analyse the cost of care. The provider 
perspective is used by researchers when they are interested in the costs borne by the provider 
(Nguyen et al., 2014). Provider costs include both the direct and indirect costs of providing a 
service. The provider costs include drug costs, consultation fees, laboratory tests, health 
workers’ salaries and so on (Drummond et al., 2005), and are usually captured through the 
assessments of patient files and cases (Nguyen et al., 2014; Ivanova et al., 2009). Some 
studies took the patient perspective, concentrating on the costs borne by the patients 
themselves (Ilesanmi, Ige & Adebiyi, 2013; Maetzel et al., 2004). The common costs 
assessed included travel costs, consultation fees, admission fees, indirect costs and laboratory 
costs. 
Though some studies use the same perspective (i.e. provider perspective), the choice of 
the costs considered differed across the studies. Some studies focused on all direct medical-
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care costs, meaning that they considered both the direct medical-care costs and the direct 
non-medical-care costs associated with the disease (Le et al., 2012). An example of a direct 
medical-care cost is drug cost, while examples of indirect medical-care costs include 
administration and transport costs. Other studies focused only on the direct costs of drugs that 
were utilised by different patients (Ganiyu & Suleiman, 2014; Ivanova et al., 2009). This 
difference alone results in differences in the cost of care, even within the same region.  
The type of costs considered in the studies is also a major factor contributing to the 
differences in costs of care. Some studies make use of financial costs (Ilesanmi, Ige & 
Adebiyi, 2013), while other studies make use of economic costs. Financial costs refer to the 
actual costs of care paid for the actual use of certain resources (or accounting costs). 
Economic costs refer to the opportunity costs of each resource utilised: for instance, when 
conducting a costing study using economic costs, donated goods will have not a value of zero 
but rather their actual resource value had they not been donated (Drummond et al., 2005). 
Economic costs capture a more accurate value of the resources than financial costs (Creese & 
Parker, 1994). Inconsistencies in the inclusion of and estimation methods for indirect costs of 
care were also seen among the different papers. Indirect costs refer to the best forgone use of 
time and are measured as the loss of income to the individual or to the household (Drummond 
et al., 2005; Creese & Parker, 1994). From a provider perspective, these can be the average 
resource use per visit, while, from a patient perspective, they could refer to the opportunity 
cost of being at the facility (i.e. lost income or lost time). If costing studies use different 
methodologies, the costs of care measured will differ and, most importantly, the results will 
not be comparable. 
Some costing studies are incomparable for many reasons. Based on the articles listed in 
Appendix A, the methodologies are not consistent. Some researchers make use of secondary 
data sets to draw up their costing data (Balu & Thomas, 2006), while others make use of 
study tools like questionnaires (Le et al., 2012; Al-Efan, 2009). Even the perspective taken 
differs with each study, with some deciding to use the patient perspective, some using the 
provider perspective and others using the societal perspective. Because there is no gold 
standard when it comes to doing a costing study, the costs measured will always differ and 
comparisons between studies will be difficult. The societal perspective is the most 
comprehensive way of doing a disease-specific study as it captures all the costs involved 
(Drummond et al., 2005). Looking at Appendix A, costing studies are also presented in 
different currencies and periods. The results are presented as a monthly cost, an annual cost 
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or, sometimes, as an incremental cost. This makes comparing the results among countries 
difficult, especially if the results are presented in different currencies. Regardless of all these 
issues, all costing studies on hypertension cost show that the cost of care is high. 
Despite the high cost of care and various methodologies for costing, hypertension on its 
own is generally undermanaged, with a small percentage of the patients achieving the 
required blood pressures. For example, in a study by Ilesanmi et al., (2013), only 33.6% of 
the study population achieved the desired blood pressure, owing to non-persistence and non-
adherence to medication. In South Africa, more than 50% of people who are on 
antihypertensive medication have uncontrolled hypertension (Carter, Bosworth & Green, 
2012). Uncontrolled hypertension is defined by a blood-pressure measurement that is above 
140/90 mmHg (Steyn et al., 2001). Many people with hypertension in South Africa have 
uncontrolled hypertension (Steyn et al., 1999).  
 
3 Objectives 
The overall objective of the study is to estimate the cost and cost-effectiveness of using a 
mobile-phone SMS system to improve adherence and health outcomes in hypertensive 
patients attending Vanguard Community Health Centre. 
3.1 Specific Objectives  
The specific objectives are to: 
• estimate the cost of providing hypertension care from both the health service and the 
patient perspective (societal perspective). 
• estimate the economic cost of the SMS-text intervention used in the StAR* trial under 
routine care. 
•  establish the cost effectiveness of the SMS-text intervention compared to that of the no-
intervention status quo.  
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4 Conceptual Framework 
In this study we will identify and measure all costs related to hypertension, i.e., (1) what does 
it cost to provide hypertension care (both in current practice and in SMS-text intervention), 
and (2) what is the cost and the economic burden to the patient of accessing and receiving 
hypertension care (in current practice)? Costs consist of both direct and indirect costs. 
Intangible costs such as the cost of suffering and pain will not be considered in this study 
owing to their complexity and the difficulty of measurement. Direct costs consist of direct 
medical costs (DMC) and direct non-medical costs (DNMC), of which both can be incurred 
by patients and providers. An example of a direct medical cost is drug cost; an example of a 
direct non-medical cost is transport cost. Indirect costs refer to the productivity loss incurred 
by individuals and households while seeking care (Weinstein et al., 1996). Loss in 
productivity because of absenteeism and loss of leisure time are examples of indirect costs. 
We will estimate both financial and economic costs. Financial costs refer to actual monetary 
expenditure on goods and services, while economic costs refer to the opportunity cost of the 
resources used (Creese & Parker, 1994). Using economic costs allows us to capture the value 
of donated resources as well as that of voluntary labour (Creese & Parker, 1994). Figure 1 
shows the framework of the cost categories. 
Figure 1: Framework of the Cost categories
 
Source: Adapted from Graden, S., (2003) 
 















5.1 Study design 
A retrospective cost analysis of hypertension care from the provider perspective will be 
conducted and will be complemented by a costing study from the patient perspective. 
Different methods will be used to cost hypertension care for each perspective (see Table 1). 
The ingredients approach (sometimes referred to as “bottom-up costing”) and step-down 
costing will be used to cost hypertension care from a provider perspective, as was done in 
other studies (Settumba et al., 2015; Hansen et al., 2000). A patient-exit survey, which 
involves the administration of a questionnaire to patients, will be conducted to estimate the 
cost of hypertension from the patient perspective. Both financial and economic costs will be 
estimates, since the SMS mobile-intervention programme within the trial was provided 
largely free of charge. All costs will be estimated in 2016 South African Rand (ZAR). The 
study sample for the patient perspective will mimic the characteristics of the StAR* trial 
population sample in terms of demographics. Finally, cost estimates from the cost analysis 
will be combined with the outcome results from the StAR* trial to establish the cost-
effectiveness of the StAR* mobile-phone intervention.  
 
5.2 Study setting  
 
The study population includes hypertension patients at the Vanguard Community Health 
Centre (CHC), situated in Bonteheuwel, Cape Town, Western Cape. Vanguard CHC serves 
the people of Langa and Bonteheuwel by providing a range of health services. The clinic 
serves approximately 28,000 patients a month, while the clinic for chronic diseases serves on 
average 500 patients a week (Bobrow et al., 2014).  
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5.3 Sample size 
The sample size is based on that of the StAR* trial population 1372. Using a margin of error 
of 5%, a confidence interval of 90% and a response distribution of 50%, the sample size (n) is 
calculated as follows: 
𝑆𝑎𝑚𝑝𝑙𝑒 𝑠𝑖𝑧𝑒 (𝑛) =  
𝑍2 × 𝑝 × (1 − 𝑝)
𝑑2
Eq. 6.1 
Where: Z = Z value (e.g. 1.645 for 90% confidence level)  
p = probability of non-response 
d = margin of error 
The sample size is equal to 227. Assuming a 10% non-response rate, the final sample will 
consist of 250 individuals.    
5.4 Sampling 
Given that the StAR* study is complete, we will assume that by using the same inclusion 
criteria and population, we will interview the same people that would otherwise have been 
involved in the StAR* trial. On the day of the interviewer’s visit to Vanguard CHC, all 
hypertensive patients presenting to the health facility will be interviewed. If many patients are 
presenting, systematic sampling with an equal probability method will be applied using the 
appointment schedule. We will approach the healthcare staff at the beginning of the day on 
randomly selected days and ask for a list of the patients to be seen that day for hypertension 
(if available). We will approach the patients after their healthcare visit and invite them to 
complete the questionnaire. For those that collect their medication on separate sites using 
“adherence clubs”, we will participate in some of the clubs’ meetings and invite the patients 
there to complete the questionnaire. Individuals that are in a hurry and do not wish to 
complete the questionnaire will be asked if the interview can be conducted over the phone at 
their convenience. Interviews will be stopped once we reach our target sample-size of 250 
patients. Careful consideration will be taken to match the demographics of the StAR* study 
by doing preliminary analysis of our data. 
Patients will be interviewed who (1) meet the inclusion criteria and (2) provide written 
consent to participate in the study.  
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Inclusion criteria:  
- Patients older than 21 years (as per the StAR* study); 
- Patients providing written consent to participate in the study;  
- Patients who have hypertension (identified using the ICD-10 code I10); 
- Patients on antihypertensive medication or those about to start taking them; 
- Patients with a blood-pressure measurement of <220/120 mmHg at enrolment;  
- Patients that reside in Langa or Bonteheuwel.  
Exclusion criteria:  
- Patients who do not have hypertension; 
- Patients who do not provide written consent; 
- Patients who are pregnant, with a blood pressure of >175/105 mmHg and symptoms 
of hypertensive emergency (i.e., headache, chest pain, seizure, oedema, etcetera). 
 
5.5 Assessment of costs from the perspective of the health provider. 
We will estimate the total cost of hypertension for each intervention (current practice and 
SMS-based intervention) and the unit cost per outpatient visit to the CHC. Provider costs will 
include costs from the CHC. The total cost of hypertension from the provider perspective will 
be estimated using a combination of the ingredients approach and step-down costing. The 
ingredients approach will be used to estimate the direct medical costs of hypertension care at 
the CHC, while the step-down approach will be used to estimate the cost per outpatient visit. 
The latter approach includes only the non-medical recurrent and capital costs. 
Ingredients Approach: To estimate the direct medical costs of care we will use the ingredients 
approach, whereby resource usage (the quantity of inputs used to provide the intervention) is 
multiplied by the resources’ respective prices. Direct medical-care costs such as drugs, 
laboratory tests, diagnostic tests and consultation fees will be calculated using this method. 
We will work with local clinicians to develop a list of ingredients that represent a typical 
encounter for hypertension care. These ingredients will be checked against the medical 
records of participants in the StAR* trial. 
Step-down Costing: This method will be employed to capture the non-medical costs used to 
deliver hypertension care. Like in other studies, step-down costing will be used to allocate the 
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costs of running the CHC to the final cost centres where direct provision of hypertension care 
is provided (Free et al., 2013; Drummond et al., 2005; Creese & Parker, 1994). Step-down 
costing will be performed, as described by Conteh and Walker (2004). The various 
departments at Vanguard CHC will be divided into final, intermediate and overhead cost 
centres (Hansen et al., 2000). Final cost centres refer to those centres that provide medical 
services directly to patients – in this study, the outpatient department. Intermediate 
departments provide support services to the final cost centres, such as diagnostic services or 
drugs, which are supported through the laboratory and pharmacy units, respectively. 
Overhead cost centres are the departments/units that provide general support services that are 
necessary to run the CHC (Afriandi et al., 2010; Weinstein et al., 1996; Creese & Parker, 
1994) such as administration, cleaning, and maintenance. The costs of the support and 
overhead departments will be allocated to the final cost centre (outpatient department) in a 
stepwise fashion. The overhead departments are placed first in the step-down procedure, 
since they provide services to the whole CHC. Intermediate centres are placed second, since 
they do not provide services to the overhead centres. Final cost centres are placed last.  
Once the cost centres have been identified, we will first assign recurrent and capital costs to 
the various cost centres directly, based on their actual resource usage (Hansen et al., 2000). 
For example, the salary cost of a nurse will be allocated to the outpatient department based on 
the proportion of time he/she spends in the outpatient department, the salary cost of 
administrative staff will be allocated to the administration cost centre, and so on. Once all 
recurrent and capital costs have been allocated to the various costs centres, the next step 
involves the allocation of overhead costs to the intermediate and final cost centres. In the 
third and final step, the costs of running the intermediate cost centres will be allocated to the 
final cost centre. Once all the costs have been allocated to the final cost centres, the total cost 
of the outpatient department will be divided by the total number of outpatient visits to get the 
unit cost per outpatient visit. The total cost of hypertension care per patient will then be 
obtained by adding the unit cost per outpatient visit to the average medical cost per person 
(obtained using the ingredients approach). 
Recurrent costs are resources that have a useful lifespan of less than one year, while capital 
costs are resources with a useful lifespan of more than one year (Creese & Parker, 1994). 
Capital costs will be valued according to their replacement costs. To allow for depreciation 
and the opportunity cost of purchase, capital items will be annualised using a discount factor 
of 3% (Drummond et al., 2005). Discount rates of 0%, 5% and 10% will be used in the 
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sensitivity analysis. The estimated lifespan used for buildings, furniture and vehicles will be 
30 years, 10 years and 5 years, respectively (Drummond et al., 2005; Creese & Parker, 1994).  
Data collection: For the ingredients approach, data on direct medical costs and service 
utilisation will be obtained from medical records. We will review approximately 200 medical 
records and collect information on demographic characteristics, patient visits, attendance, 
blood-pressure tests and medication. In addition to the information collected from medical 
records, direct non-participatory observation will be done to understand the current patient-
management process for hypertension (length of the patient-provider contact, types of 
services provided, etc.). Observations will be conducted for 30 patients. Structured interviews 
will be conducted with the CHC staff involved in the StAR* trial to collect information on 
the different activities related to hypertension care as well as on the length of time spent on 
these activities. Once the care pathway is established, we will list the ingredients and check 
them against the StAR* participants’ medical records. Adjustments will be made to reflect 
how utilisation differs (in terms of ingredients consumption) between the intervention and 
usual-care participants.  
The information for the step-down costing will be obtained from the most recent financial 
records (for recurrent expenditures). If personnel costs are not found in the financial records, 
a list of the staff who work in the departments of interest will be compiled and their salaries 
will be allocated according to their salary grades. An inventory list will be made (if one is not 
available) to capture capital items such as building, furniture and vehicles.   
 
5.6 Assessment of costs from the perspective of the patient 
Iinformation on direct (medical and non-medical) and indirect costs of hypertension from the 
patient perspective will be collected using a patient-exit survey. The survey will collect the 
following information: 
- Demographic variables (age, gender, race, education, marital status, etc.); 
- Health-seeking behaviour (frequency of clinic visits per month); 
- Information on care received (type of care received, duration, type of drugs, dosages, 
medication instructions, etc.); 
- Direct medical and non-medical costs (transport costs, food, administration costs, 
drug costs, consultation costs, under-the-table costs); 
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- Socioeconomic status, indirect costs and impact of disease (education, income, coping 
strategies).  
Direct costs consist of out-of-pocket expenditure on medical inputs (consultation, drugs and 
laboratory tests) and non-medical inputs such as food costs and costs for transportation to and 
from the health facility. Indirect costs refer to productivity losses incurred by the patient and 
by informal caregivers and will be estimated using the human-capital method, which consists 
of valuing the loss of income to patients and caregivers. Income will be measured by asking 
questions about monthly wages and income from various other sources (e.g. grants). The 
survey will be pre-tested through a pilot study prior to data collection.  
Pilot study: A pilot study will be conducted at Vanguard CHC two weeks prior to the study. 
The pilot study will be done at the same centre with individuals who meet the inclusion 
criteria for the actual study, the reason for this being that we want to test whether the study 
tool measures the required information or not. Ten people will be used in the pilot study. 
Upon completion of the pilot study, we will also ask the participants whether the questions 
were simple and easy to answer. Possible responses and challenges to using the tool will be 
obtained after the pilot study and amendments will be made accordingly, to make the study 
tool maximally clearer to the study population. 




Table 1: Summary of costing and data-collection methods 
 Perspective 
 Provider  Patient 
Methods Ingredients 
approach 











transport and food) 
Indirect costs 
(Productivity loss) 
Data Sources Medical records 
and direct 
observation 




cost per patient 
(a) 
Median cost per 




Median loss of income 




(a)+(b) = Median cost of 
hypertension-care per outpatient visit 
(b) + (d) = Median cost incurred by 
households per hypertension-care outpatient 
visit 
 Median cost per hypertension care outpatient visit 
Source: Adapted from Meheus et al. (2013) 
5.7 Cost-effectiveness of SMS-based interventions  
The study’s objective will be met by analyzing the collected data. Two outcomes will be used 
in the cost-effectiveness analysis: 1) the odds of adherence, and 2) the average reduction in 
blood pressure. Data on the patient outcomes will be obtained from the StAR*-trial 
investigators. The difference in costs and outcomes in the intervention versus in current 
practice will be presented as an incremental cost-effectiveness ratio (ICER). 
 𝐼𝐶𝐸𝑅 =
𝐶𝑜𝑠𝑡𝑠 𝑜𝑓 𝑆𝑡𝐴𝑅 ∗ −𝐶𝑜𝑠𝑡𝑠 𝑖𝑛 𝑠𝑡𝑎𝑡𝑢𝑠 𝑞𝑢𝑜
𝑂𝑢𝑡𝑐𝑜𝑚𝑒 𝑖𝑛 𝑆𝑡𝐴𝑅 ∗ −𝑂𝑢𝑡𝑐𝑜𝑚𝑒 𝑖𝑛 𝑠𝑡𝑎𝑡𝑢𝑠 𝑞𝑢𝑜
 q. 6.2 
Adherence and blood-pressure reduction are the main outcomes of interest in the study. The 
units of analysis will thus be “cost per adherent patient” and “cost per mmHg blood-pressure 
reduction”, respectively. 
5.8 Sensitivity Analysis 
When doing economic evaluations, a lot of assumptions that may influence the results are 
made. To ensure that the results are comparable across different studies, a sensitivity analysis 





findings while allowing for generalizability to other research settings (Walker & Fox-Rushby, 
2001). We will conduct a one-way sensitivity analysis. The effect of changes in parameters 
(consultation times, SMS costs, discount rate, utilization between interventions, etc.) will be 
assessed one parameter at a time.  
5.9 Data Analysis 
Data will be double-entered using Epidata® software. Upon completion, both files will be 
compared to ensure consistency. Should mistakes and discrepancies be found, the 
investigator will correct them after reviewing the original forms. Data will be analyzed with 
STATA (version 13, Texas: StataCorp) and Microsoft Excel. Continuous variables will be 
analyzed using means/medians and standard deviations/interquartile range, while categorical 
variables will be analyzed using proportions. The cost of care will be compared across the 
mobile intervention and the normal standard of care. Differences in the cost of care between 
different models of care in hypertension at the CHC will be compared (i.e. adherence clubs 
versus those who are not part of such clubs). 
6 Ethical Issues 
The ethical and legal issues within this study are limited. The analysis of cost and cost-
effectiveness is based on data derived mostly from the StAR* project, which already has 
ethics approval from the University of Cape Town Human Research Ethics Committee 
(UCT-HREC) (reference [418/2011]). A copy of that project’s ethics approval is attached to 
this document. In order to carry out this phase, ethics approval will be sought from the UCT-
HREC. 
6.1.1 Risks and benefits 
The study entails minimal risk to the patients and health staff. The provider surveys do not 
bring any risk. The patient-exit survey may cause some minor psychological discomfort to 
the respondent. The survey also questions the respondent on sensitive issues related to their 
income and the income of his or her household. To minimize the discomfort, the respondent 
will be interviewed in a separate room or some other location away from bystanders. There 
are no direct benefits to the participants of the study as we will not provide any treatment 
(nor, however, will any treatment be withheld). No financial or other benefits will be 
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provided to participants. The study will provide information on the costs of hypertension 
from a societal perspective. The indirect benefit of the study is that the Department of Health 
and policymakers will learn about the costs of hypertension and the costs of the mobile-based 
intervention; in the long run, such information may be used to decide how best to manage 
hypertension.   
6.1.2 Informed Consent 
Participation in the study is voluntary and participants (patients and health staff) will be asked 
for written informed consent, which will offer the possibility to withdraw from the study at 
any moment without negative consequences for the interviewee. The informed consent will 
be written in English, IsiXhosa and Afrikaans. The information sheet and consent form will 
have information on the purpose, procedures, risks and benefits of conducting the study of 
cost and cost-effectiveness (see Appendices B and C). Trained interviewers will administer 
the informed consent to the participants as well as explain everything related to the study and 
the consent forms. Respondents that decline to provide consent will be excluded from the 
study. 
6.1.3 Privacy and confidentiality 
We will anonymize the data and protect the confidentiality of participants, by taking the 
following measures: 
- Interviewers will sign the consent form to ensure the confidentiality of all collected data
and will receive training on how to maintain patient confidentiality;
- Real names and other personal identifiers will not be used in the study;
- We will not record the names of participants on the patient survey forms. The survey
forms will be linked to the participants’ consent forms using the survey-form numbers;
- The participant’s consent forms will be stored in a locked filing cabinet. Electronic data
will be password-protected and accessible only to members of the research team;




 An estimate of the budget is summarized in Table 2 
Table 2: Budget outline 
Item 





distance 19 km 
per day) 
Travel to and from the facility (average 
distance 19 km at R3/km) Total km= 1040 
km 
1040 3 3120 
Stationery Pens, pencils, highlighters, etc.   200 
Printing Informed consent (1 page * 0.3) 260 0,3 78 
 Information leaflet (2 pages * 0.3) 260 0,6 156 
 Patient questionnaire (15 pages * 0.3) 260 4,5 1170 
 Provider questionnaire (2 pages * 0.3) 10 0,6 6 




Patient questionnaire (15 pages) * 2 30 350 10500 
 Informed consent (1 page) * 2 2 350 700 
 Information leaflet (2 pages) * 2 4 350 1400 
Fieldworker(s) All costs including travel and food   20000 
Total amount    37339 
 
The travel distance was based on the number of kilometers between the University of Cape 
Town (UCT) medical campus and Vanguard Community Health Centre (calculated, using 
Google Maps, as 9.5 km one-way) multiplied by the number of days of the research. The unit 
price of printing is based on the UCT 2016 printing rates (R0.3 per page). The patient 
questionnaire, the information sheet and consent form will be translated into isiXhosa and 
Afrikaans based on a per-page rate (R350 per page). In the Western Cape, isiXhosa and 
Afrikaans are the dominant languages spoken. Professional translation will be required for 





The timeline of the study is provided in Table 3. 
Table 3: Gantt chart 












Apr May Jun 
Proposal 
Development     
  
    
      
Submission for 
Ethics Approval           
      
Data Collection                 
Data Analysis                 
Report write up                 
Submission of 
Report               
  
Dissemination                 
 
7.2 Dissemination of Findings 
The study will be submitted in fulfilment of the Master’s in Public Health programme at the 
University of Cape Town. Research findings will be disseminated through (1) one scientific 
publication in a national or international peer-reviewed journal, (2) a policy brief, (3) a 
summary report for Vanguard Community Health Centre and the Western Cape Provincial 
Department of Health, and (4) a presentation at a national or international conference. The 
study is a collaboration between the University of Cape Town, the University of Oxford, the 
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9 Introduction  
Text messaging based interventions are increasingly being used in chronic disease 
management such as hypertension to improve patients’ medication adherence and compliance 
(Beratarrechea et al. 2014). Medication adherence and compliance has been linked to an 
improvement in patient outcomes by increasing the chances of achieving the desired 
outcomes (i.e. desired blood pressure level).  When patients with hypertension are compliant 
and adhere to their medication, less complications are observed (Klein 1988).  In the long 
run, this may reduce the level of health service utilization and costs by avoiding more 
complicated treatment plans related to uncontrolled hypertension and other Non-
Communicable Diseases (NCDs) that are on the rise worldwide. 
I shall review the literature on innovative techniques for hypertension management, 
focusing primarily on mobile health interventions (mHealth). This literature review is 
organised as follows. In Section 10, I will describe the epidemiology and present data on the 
burden of hypertension globally and in Africa. In Section 11, I present a brief methodological 
overview of economic evaluation. I will describe what the different types of economic 
evaluation techniques are, and focus in more detail on the identification and measurement of 
costs. In Section 12, I will present cost-effectiveness studies for mHealth interventions and 
the findings of the review for cost-of-illness studies of hypertension. The last section 
concludes  
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10 Epidemiology of hypertension 
10.1 What is Hypertension 
Blood pressure refers to the force that is exerted onto blood vessels by the blood as it moves 
through them after being pumped by the heart (Saladin, Miller 1998). Normal blood pressure 
in adults is 120/80 mm Hg (Cappuccio, Capewell 2015). The first number is the systolic 
blood pressure and the second number is the diastolic blood pressure. As blood pressure 
increases, it becomes harder for the heart to pump and this increases the risk of damaging the 
blood vessels and the heart (Saladin, Miller 1998). Hypertension (or raised blood pressure) is 
defined as having a blood pressure that is equal to or greater than 140/80 mm Hg (Program, 
National High Blood Pressure Education 2000). Individuals with a blood pressure 
measurement between 120/80 mmHg and 140/90 mmHg are pre-hypertensive (Peer 2013, 
Chobanian et al. 2003). To diagnose hypertension, three physical blood pressure 
measurements are taken in a clinical setting; should the readings be more than 140/90 mm Hg 
on two or more occasions, then the individual is hypertensive (Chobanian et al. 2003).  
Hypertension is asymptomatic in most individuals, making its detection a challenge (Cohen 
2009a). It is often referred to as the “silent killer” as many people are not aware that they 
have the condition (Eksteen 2015). As a result, hypertension is under diagnosed and 
undertreated globally (Steyn et al. 2001).  Several factors contribute to the emergence of 
hypertension in the population. The causes and risk factors of hypertension can be 
broadly divided into social determinants and behavioural risk factors. An ageing 
population and rapid urbanisation are examples of social determinants. As people get 
older, blood vessels thicken and get narrower, increasing the risk of hypertension. On the 
other hand, rapid urbanisation is characterised with the rapid change in diets and lifestyle 
which puts people at risk of developing conditions such as hypertension (Hofman, Lee 
2013). Because of lifestyle changes, hypertension prevalence rates in men and women 
have increased significantly by almost 100% and 50% respectively in South Africa 
between 1998 and 2008 (Mungal-Singh 2012). Examples of behavioural risk factors 
include: lack of exercise, stress, being obese, high salt intake and excessive alcohol 
intake. Incidence of hypertension can be reduced by reducing these behavioural factors 
such as eating less salt (less than 5g per day), exercising, reducing alcohol intake and 
better managing stress (Hypertension guideline working group et al. 2014).  
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10.2 Effects of Uncontrolled hypertension 
Controlled hypertension is defined as having a blood pressure that is less than 140/90 mm Hg 
while uncontrolled hypertension is having a blood pressure above 140/90 mmHg while on 
treatment (Hypertension guideline working group et al. 2014).  Hypertension damages the 
walls of the blood vessels which may lead to conditions such as cardiac failure, stroke, 
congestive heart failure, kidney failure and heart diseases (Cappuccio, Capewell 2015). On its 
own, hypertension is the leading cause of cardiovascular diseases (CVDs). From as low as 
115/75 mmHg, the risk of CVDs doubles with every 20/10 mm Hg increase in systolic and 
diastolic blood pressure (Chobanian et al. 2003). In South Africa, it is estimated that 4 in 
every 10 adults aged over 25years have hypertension and less than 50% of them know that 
they have the condition (The South African Hypertension Society 2015) and more than 50% 
of people who are on antihypertensive medication have uncontrolled hypertension (Carter, 
Bosworth & Green, 2012).  More and more people suffer and die prematurely due to strokes, 
renal diseases, heart attacks and organ damages which are a result of untreated hypertension 
(Steyn et al. 2001). According to the WHO, hypertension on its own was responsible for 
12.8% of all deaths in 2012 (World Health Organisation 2015). Maintaining hypertension 
levels to below 140/90 in individuals may reduce the incidence of the strokes, myocardial 
infarctions and kidney problems among other conditions. 
10.3 Global distribution of Hypertension 
NCDs are a group of diseases that are not transmissible amongst individuals.  The four main 
types of NCDs are chronic respiratory diseases, cancers, cardiovascular diseases and diabetes 
(World Health Organisation 2015). For the past few years, NCDs have been on the rise 
globally. In 2012, 38 million of the reported 56 million deaths worldwide were because of 
NCDs (World Health Organisation 2015). Of all forms of NCDs, cardiovascular diseases are 
the main cause of death (World Health Organisation 2015). In 2012 alone, CVDs were 
responsible for 17.5 million deaths worldwide with stroke and ischemic heart diseases 
causing 6.7 million and 7.4 million deaths respectively (World Health Organisation 2015). 
The distribution of NCD related deaths and prevalence is disproportionate across different 
regions. High income countries have the highest prevalence rates while low income countries 
have the lowest prevalence yet more deaths occur in low income countries. Recognising the 
rise of NCDs as a public problem, the WHO drafted an action plan to tackle the NCDs. One 
of the targets stipulated in the action plan involves achieving a 25% reduction in the 
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prevalence of hypertension by 2025. Managing hypertension is among the best buys 
recommended by the WHO to prevent CVDs and other conditions that may occur because of 
untreated hypertension (Bloom et al. 2011).  
 Untreated hypertension may lead to conditions such as strokes, heart attacks and 
kidney diseases which often results in premature deaths (Steyn et al., 2001). On its own 
hypertension complications account for 9.4 million deaths globally (WHO 2017). With a high 
prevalence rate for hypertension, the incidence of related NCDs increases. The prevalence 
rate of hypertension has risen by approximately 67% between 1999 and 2010 (The South 
African Hypertension Society 2015).  High income countries have the highest prevalence in 
hypertension cases compared to middle and low-income countries (WHO 2017. According to 
the WHO, hypertension prevalence is highest in Africa (46%) compare to other regions 
(World Health Organization 2014). The high prevalence of hypertension in Africa is likely 
due the high population density compared to high income countries and weak health systems 
resulting into more undiagnosed and untreated hypertension (Chobanian et al. 2003).  
Globally hypertension is under diagnosed and undertreated (Steyn et al., 2001). 
 
10.4 The importance of Hypertension and NCDs in South Africa 
An estimated 6.3 million people in South Africa suffer from hypertension (The Heart and 
Stroke Foundation, 2015). On its own, hypertension is the most common condition in South 
Africa (Steyn, Fourie & Temple 2006, Mash et al. 2012). Its prevalence rate rises with age; 
thus, hypertension is more common in the elderly population (Shisana et al. 2013). South 
Africa has a large proportion of the elderly, which makes it more prone to many hypertension 
cases (Eksteen 2015). According to South African National Health and Nutrition 
Examination Survey, the reported hypertension prevalence amongst South Africans over 15 
years of age was 10.2% in 2013 (Shisana et al. 2013). The overall hypertension prevalence 
among 25 year olds in South Africa rose from 23.9% in 2001 to 40% in 2010 (Steyn et al. 
1999, Day et al. 2014). Results from a study on Global Ageing and Adult Health (SAGE) 
indicate that South Africa has the highest hypertension prevalence among adults aged 50 
years and over (77.9%) (Lloyd-Sherlock et al. 2014). 
Hypertension alone is the most common risk factor for cardiovascular diseases 
(CVDs) in South Africa (Eksteen 2015, Cappuccio, Capewell 2015, Day et al. 2014). Thus, 
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the main reason for managing hypertension is to reduce the risk of cardiovascular events and 
other associated NCDs (Cohen 2009b). Being a major risk factor for CVDs and other NCDs, 
the rise in hypertension prevalence has also led to a rise in NCDs in the South Africa. In 
2013, strokes and hypertensive diseases were ranked third and fourth respectively on the 
causes of death list in South Africa (Mail &Guardian, 2013). In South Africa, there are about 
130 heart attacks and 240 strokes reported each day of which 50% of strokes, heart diseases 
and heart failures are a result of hypertension (The South African Hypertension Society 
2015).  
As a chronic disease, hypertension requires pharmacological and non-
pharmacological treatment for a lifetime (Pessanha et al. 2013). Patients have to be persistent 
and compliant with their medication over a long period of time for better outcomes (Graden, 
2003). Even with an effective supply of anti-hypertensive drugs, there still exists a gap 
between the desired BP control and the actual achievement (Peer 2013). Moreover, 
hypertension and its sequelae (CVD) are associated with high costs to the health sector as 
well as loss of human capital due to morbidity and premature mortality. These costs can lead 
overtime to substantial reductions in the macro-economic output (GDP) (Abegunde et al. 
2007). Hypertension requires a large investment to maintain the recommended blood pressure 
level among affected individuals (Alcocer, Cueto 2008). In the next sections, we look at how 




10.5 Management of Hypertension in South Africa 
10.5.1 Hypertension Management Approach 
Figure 1: Overview of approach to treatment 
 
Source: (Hypertension guideline working group et al. 2014) 
 
Figure 1 shows the overall approach to hypertension treatment in South Africa (Hypertension 
guideline working group et al. 2014). Before a person is diagnosed with hypertension, three 
separate blood pressure readings are taken on separate occasions. If at least two of the 
readings are above the threshold (140 mmHg) then the person is diagnosed with 
hypertension. Lifestyle modification strategies such as exercising, consuming less salt and 
reducing alcohol intake are recommended at the first step of hypertension management in 
newly diagnosed patients (table 1).  Newly diagnosed patients are informed of the lifestyle 
Measure BP at least 
three ocassions
BP 140-159/90-99 
mmHG with ≥3 risk 






mmHG with ≥3 risk 









and commence two 
drugs preferably in 
fixed-drug combination, 
review in 4=6 weeks
Not at goal




modification strategies that they should follow to control their blood pressure. If their blood 
pressure is too high, then the physician will decide whether to add monotherapy (one drug) or 
use more than one antihypertensive drug to complement the lifestyle modification strategy. 
The drugs of choice in the management of hypertension in South Africa include, Thiazide 
diuretics, Beta-blockers, ACE-inhibitors, Diuretics and Potassium sparing diuretics. A more 
detailed step by step guideline of hypertension management is provided in a separate 
document (Hypertension guideline working group et al. 2014).  
Table 1: Recommended Dietary modifications 
Modification Recommendation Approx.  ↓ SBP 
(mmHG) 
Weight reduction BMI 18.5-24.9 kg/m2 5-20 per 10 kg 
Dash diet ↓saturated fat and total fat, 
↑fruit and vegetables 
8-14 
Dietary Na* ˂100 mmol or 6 g NaCl/day 2-8 





No more than two drinks per day 2-4 
Tobacco Complete cessation - 
Source: (Hypertension guideline working group et al. 2014) 
Several tests are conducted for the diagnosis and management of hypertension. The 
recommended tests that are run for each patient from time to time based on their risk profile 
include: urine tests, blood tests, creatinine tests, cholesterol tests and fasting glucose tests. 
The following tests are done during each clinic visit; measurement of waist circumference, 
blood pressure measurement, urine tests and assessment of the Body Mass Index (BMI). 
Tests that are done at least once a year based on how the patient is doing or reacting to the 
treatment include: blood tests, creatinine tests and uric acid tests. Table 2 shows the summary 






Table 2:Summary of hypertension routine Investigations 
Test Comment 
Height, weight, BMI Ideal BMI <25kg/m2, overweight 25-30 kg/ m2, obese>30kg/ m2. 
Waist circumference Men<102 cm; women<88cm. South Asians and Chinese: men<90 
cm and women <80 cm. 
Electrolytes Low potassium may indicate primary aldosteronism, or effects of 
diuretics. 
ECG S in V1 plus R in V5 or V6 >35mm or R in a VL>11 mm or 
Cornel product (R in aVL+ S in V3 +6 in females) * QRS duration 
>2440 (mm/ms).
Electrocardiogram (if indicated 
and facilities available) 
LVH: men> 115 g/ m2 and women > 95 g/ m2. 
Fasting glucose Consider HBA, or GTT if impaired fasting glucose (6.1-7.1 
mmol/l). 
Cholesterol If cholesterol˃ 5.1 mmol/l-fasting lipogram. 
Creatinine Calculate eGFR. 
Uric acid High uric acid is relative contraindication to diuretics. 
Dipstick If abnormal, urine microscopy and protein stimulation. 
Source: (Hypertension guideline working group et al. 2014) 
10.5.2 Hypertension Care in South Africa 
Hypertension care is provided free of charge at primary health care facilities in South Africa 
and is most commonly managed on an outpatient basis, whereby patients visit the primary 
health care facilities every month for medical check-ups as well as medication pick-ups. 
Diagnosis of the condition is made by the doctor while nurses conduct blood pressure tests 
and other required tests each time the patient visits the clinic as well as counselling the 
patients. Pharmacists dispense the medication to the patients with hypertension. If the 
primary health care facility visited is a clinic which does not have a pharmacist, a nurse may 
dispense the prepacked anti-hypertensive medication to the patients. 
Based on the status of the patient’s hypertension (controlled or uncontrolled), treatment 
pathways at public health care facilities may differ. In general, patients with hypertension are 
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scheduled to visit the primary health care facility at least 12 times a year regardless of the 
status of their hypertension. Uncontrolled hypertension patients visit the facility more than 
controlled patients for check-ups and titration of medication doses until their blood pressure 
is well managed and controlled.  The main difference in the number of scheduled visits 
between the two groups of patients is that controlled hypertension patients make 10 pharmacy 
visits and 2 follow-up visits to the public health facility while uncontrolled hypertension 
patients make follow-up visits only which may be more than 12 in a year.  Pharmacy visits 
are less resource intensive as patients only visit the pharmacy to collect their medication, 
while follow-up visits are more resource-intensive because multiple health professionals 
(nurse, doctor, and pharmacist) are involved.  
 
10.6 Novel approaches to improve adherence in Hypertension  
 
Hypertension treatment is lifelong and requires patients to take one or more tablets once 
or twice a day. The effectiveness of a treatment program for managing hypertension 
therefore depends on the patient taking their medication. Studies show that improving 
medication adherence produces better disease outcomes (Kiselev et al. 2012, Hamine et al. 
2015). Non-adherence on the other hand leads to complications and wastage of resources 
(Alcocer, Cueto 2008). Considering that the treatment of hypertension is lifelong, non-
adherence further increases its prevalence and costs of managing hypertension also increase.  
Interventions such as nurse or pharmacist led interventions and others including mobile 
health (mHealth) interventions have been developed to better manage hypertension. This 
study focuses on the application of mHealth to improve hypertension management. The next 
section focuses on mHealth and its application in hypertension. 
 
10.6.1 Mobile Health (MHealth) 
 
MHealth makes use of mobile phones to facilitate communication between health providers 
and patients within the health sector (Adibi 2015). In the healthcare sector, the use of mobile 
phones is increasing due to the rapid advancements in mobile technologies and the 
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availability of mobile phones within the population (Leon, Schneider & Daviaud 2012). In 
South Africa, most of the population (rich and poor) owns a mobile phone and can therefore 
be reached, irrespective of their social status (Leon, Schneider & Daviaud 2012). MHealth 
makes it possible for practitioners to communicate with patients on a larger scale 
instantaneously (Carter, Bosworth & Green 2012), plus it reduces barriers that often reduce 
access to care such as distance to the facility (Leon, Schneider & Daviaud 2012). 
Mobile phones have previously been used in the management of chronic diseases such 
as asthma, obesity, hypertension and diabetes (Nundy et al. 2012). The use of mHealth in 
hypertension and other chronic diseases has been found to be effective in (1) improving 
hypertension outcomes (2) improving adherence and (3) improving self-care and 
management (Hamine et al. 2015). Several studies have looked at the potential benefits of 
using mobile-based applications to support people with hypertension. A study by Kiselev et 
al. (2012) compared the use of a mobile technology in patients with arterial hypertension with 
those under the traditional care. 77% of the people in the mobile base management achieved 
the desired blood pressure control. The result was reported to be 5 times higher than those 
that were in the traditional care (Kiselev et al. 2012). 
 MHealth was also shown to improve blood pressure control if it is used in blood 
pressure monitoring (Logan et al. 2007).  This is because when patients can see the changes 
in their blood-pressure readings over time, they are more likely to adhere to their medication 
to achieve better blood pressure control. Randomised control trials also show an 
improvement in controlling blood sugar and blood pressure when mHealth is used (Fischer et 
al. 2012, Earle et al. 2010, Logan et al. 2007). MHealth, unlike other models of care for 
hypertension, provides a platform for engaging with patients throughout the treatment 
process, while offering real-time responses and it also allows for active patient engagement 
between providers and patients, which encourages self-management while increasing health 
awareness and patient accountability (Fischer et al. 2012). Furthermore, simple and less 
complicated mHealth interventions such as the use of SMS texts were found to be more 
favourable among individuals (Logan 2013).  
Despite the increasing use of mHealth in health care, there is a lack of economic 
evaluation studies on them particularly those that focus on costing the interventions. In South 
Africa, there is a lack of studies that have assessed the cost of hypertension. To cost 
hypertension and an mHealth intervention that was conducted in South Africa, this literature 
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review explores the literature that is available on the economic evaluations of mHealth and 




11 Introduction to Economic Evaluation and Costing 
11.1 Economic evaluation 
11.1.1 The role of economic evaluation 
 An economic evaluation is a systematic method that is used to compare two or more 
interventions in terms of their costs and outcomes (Acharya et. al., 2011). Economic 
evaluations improve decisions on the allocation of resources by making comparisons between 
mutually exclusive and/or complementary interventions (which may include a "do-nothing" 
scenario) to ensure the best use of scarce resources (McGuire 2001). In health care, we try to 
make use of the scarce resources efficiently and equitably. Due to the scarcity of resources, 
trade-offs must be made when allocating resources. With the help of economic evaluations, 
we can justify our decisions in opting for some interventions over others. 
11.1.2  Types of economic evaluation 
Drummond et al. (2005) provides a useful classification of the different types of economic 
evaluations (table 3). Economic evaluations can be classified depending on whether (1) both 
costs and outcomes are measured, and (2) if there is a comparison between one or more 
alternatives.  Studies whereby only costs or only outcomes are assessed are considered partial 
economic evaluations. Efficacy of effectiveness studies measure only outcomes (Oparil et al. 
2007), while a cost analysis examines only the costs of a program or intervention. The latter 
provides us valuable information on the costs of the program and is an input for full 
economic evaluations (see section 11.5 for a more detailed discussion). Evaluations whereby 
both costs and outcomes are assessed, and a comparison is made between different 
alternatives are considered full economic evaluations. There are four types of full economic 
evaluations: Cost Minimisation Analysis, Cost Effectiveness Analysis, Cost Utility Analysis 




Table 3: Measurement of costs and consequences in the different types of EE 
Type of study 
Measurement/ 
valuation of costs 
Measurement/ valuation of consequences 





Natural units (e.g. life-years gained, points of 




Quality adjusted life years (QALYs), disability 





Monetary units (e.g. euro, US dollar, Swiss 
franc) 
Source: Adapted from Drummond et al. (2005) 
A cost minimisation analysis (CMA) is used when two interventions have the same 
effectiveness or outcome and the only difference between the two are the costs. The preferred 
intervention in such a case is the one with the lowest cost (Briggs, O'Brien 2001). This 
technique is not frequently used primarily because in a CMA one assumes that the 
effectiveness of different interventions is the same which is rarely the case.  In a cost-
effectiveness analysis (CEA), the outcome(s) of interest are measured in their natural units 
and the costs in monetary units (Drummond et al. 2005). The outcomes are a quantifiable unit 
which can either be behavioural (i.e. adherence to medication intake) or a health outcome (i.e. 
blood-pressure reduction in mmHg) (Robinson 1993). The results of a CEA are most often 
presented as a ratio measuring the difference between the costs and effectiveness of the 
strategies being considered. The ratio is called the incremental cost effectiveness ratio (ICER) 
and is calculated as follows: 
 𝐼𝐶𝐸𝑅 =
𝐶𝑜𝑠𝑡𝑠 𝑜𝑓 𝑆𝑡𝐴𝑅 ∗ −𝐶𝑜𝑠𝑡𝑠 𝑖𝑛 𝑠𝑡𝑎𝑡𝑢𝑠 𝑞𝑢𝑜
𝑂𝑢𝑡𝑐𝑜𝑚𝑒 𝑖𝑛 𝑆𝑡𝐴𝑅 ∗ −𝑂𝑢𝑡𝑐𝑜𝑚𝑒 𝑖𝑛 𝑠𝑡𝑎𝑡𝑢𝑠 𝑞𝑢𝑜
 Eq. 6-2 
To calculate the cost effectiveness ratio, there must be one dimensional outcome measure 
which is specific to the disease of interest (i.e. blood pressure reduction measured in mm Hg) 
that can be used to establish the net costs per unit increase or decrease in the outcome 
(Robinson 1993).  For conditions, such as hypertension, using outcome measures such as 
mmHg may not reflect the actual benefit of the program since these are considered an 
intermediary outcome as they do not necessarily give a true reflection on the effect on 
mortality. A cost utility analysis (CUA) on the other hand is able to capture and reflect the 
full impact of an intervention by considering both the quantity and the quality of life (Coons, 
Kaplan 1996).  Conditions such as hypertension may lead to strokes and myocardial 
infarctions (among other things) which often lead to disabilities and a change to quality of 
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life. It is sometimes important to use a technique which can measure utility by considering 
both the quantity and quality of life when possible because some interventions may prolong 
life and significantly improve the quality of life of individuals at the same time.  Considering 
only the quantity of life (life year saved) would undervalue the lifelong condition and this is 
where the CUA may come in.   
The two main outcome measures used in CUA are the “quality adjusted life years” 
(QALY) and the “disability adjusted life years” (DALY).  A QALY considers both the 
quantity and the quality of life. QALYs are used by health economists to correct an 
individual’s life expectancy based on their quality of life (Sassi 2006). When used within the 
context of an economic evaluation, QALYs measure the improvement in the quality adjusted 
life years resulting from the introduction of an intervention as opposed to no intervention 
(Sassi 2006). A value of 1 QALY corresponds to a year in perfect health while a value of 0 
corresponds to death (Preedy, Watson 2010). An intervention that extends life, but has an 
impact on its quality will have a QALY between 0 and 1 (i.e. a year is less than perfect 
health) (Drummond et al. 2005). The quality of life valuation is often referred to as “health 
utilities” and there are several methods to measure the individual's preferences for different 
health states (i.e. the utilities).  These include; the rating and visual analogue scale, the 
standard gamble method, and lastly the “time and person” trade off method (Bleichrodt, 
Johannesson 1997, Torrance 1987).  DALYs on the other hand represent the loss of 
functioning caused by illness (Sassi 2006) and are calculated as the sum of present value of 
future years of life lost due to premature mortality (YLL) and the present value of future 
lifetime years lost due to disability (YLD) (Rushby, Hanson 2001). One DALY corresponds 
to one year of healthy life lost and 0 represents perfect health. 
DALY= Years of life lost (YLL) + Years lost due to disability (YLD) Eq. 11-1 
Finally, a cost-benefit analysis (CBA) is a type of economic evaluation which is used when 
the outcome(s) of interest is measured in monetary terms such that the costs and outcomes are 
presented in the same units (Goodman, Ahn 1999). In a cost-benefit analysis, outcomes are 
converted into monetary terms using the Human Capital Approach (HCA), and the 
willingness-to-pay approach (Drummond et al. 2005). The HCA measures the opportunity 
cost (or productivity loss) of an individual based on income (value of life = present value of 
lifetime earnings), while the willingness-to-pay approach simply assesses the maximum 
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amount that individuals are willing to pay to reduce the probability of dying (Wonderling 
2011).  CBAs are commonly presented as a benefit-cost ratio (CBR) expressed as: 
 𝐵𝐶𝑅 =  
𝐵𝑒𝑛𝑒𝑓𝑖𝑡 𝑜𝑓 𝑠𝑡𝑟𝑎𝑡𝑒𝑔𝑦 2 − 𝐵𝑒𝑛𝑒𝑓𝑖𝑡 𝑜𝑓 𝑠𝑡𝑟𝑎𝑡𝑒𝑔𝑦 1
𝐶𝑜𝑠𝑡 𝑜𝑓 𝑠𝑡𝑟𝑎𝑡𝑒𝑔𝑦 2 − 𝐶𝑜𝑠𝑡 𝑜𝑓 𝑠𝑡𝑟𝑎𝑡𝑒𝑔𝑦 1
 Eq. 11-2 
The preferred intervention when using the CBA intervention is the one in which the 
intervention’s benefits outweigh its costs (Goodman, Ahn 1999). This makes it easier to 
compare interventions from different sectors, as it would have not been possible to do so 
unless a CBA is conducted where the outcomes are converted into monetary units. However, 
when comparing health interventions, CBA is not often used because of the difficulty of 
converting health outcomes into monetary terms. 
11.2 Perspective  
 Interventions have different costs and outcomes that affect societies differently. Based on 
who is consuming the resources, costs and outcomes of a health care intervention can be 
looked at from different perspectives. The three common perspectives that are used in 
economic evaluations are: provider perspective, patient perspective and societal perspective 
(Drummond et al. 2005). The provider perspective only considers costs of an intervention 
that are borne by the provider such as drug costs and overhead costs; costs incurred by 
patients are not considered (Creese, Parker 1994). For example, a study by Nguyen et al. 
examined the cost of hypertension from the health care provider perspective in a hospital in 
Vietnam (Nguyen et al. 2014). This study included the costs to the hospital of inpatient care 
(the cost per bed-day,) drug and laboratory costs and overhead costs.   
The patient perspective focuses on the costs that are borne solely by the patients and 
their households (Weinstein et al. 1996). These costs include direct medical costs (i.e. drug 
costs), direct non-medical costs (i.e. transport costs) and indirect costs (i.e. productivity 
losses). A cost of illness study carried out in Malawi, investigated the economic burden of 
chronic non-communicable disease using the patient perspective (Wang et al. 2016). Costs 
measured in this study included; direct and indirect costs. Direct costs on their own 
contributed 72% of the total cost. 
 The societal perspective is the most comprehensive perspective which considers the 
health benefits and profitability of interventions to the society (Jönsson 2009). When dealing 
which chronic conditions such as hypertension that have no cure, the societal perspective is 
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preferable as it delineates all the positive and negative effects of an intervention together with 
its costs and how they affect the society. Since both the provider and the patient are subjected 
to a lifetime of hypertension related costs, it is only logical to consider all costs involved 
regardless of who bears them. In South Africa, the costs related to hypertension from the 
provider perspective in the government sector where primary health care services are 
provided free of charge include; drug costs, consultation costs, laboratory tests and overhead 
costs. Costs borne by the patient while accessing hypertension services include direct non-
medical (i.e. transport costs) and indirect costs (i.e. productivity losses).  
11.3 Assessment of costs 
A cost analysis refers to the quantification and valuation of all the resources that are used in 
an intervention (Drummond et al., 2005).  It is also the first part of an economic evaluation 
which is used to assess the cost of care in most disease-specific costing studies (Weinstein et 
al. 1996). Unlike other economic evaluation methods, a cost analysis does not involve the 
outcomes; hence, it is referred to as a partial economic analysis (Drummond et al. 2005). The 
cost analysis element forms an integral part of economic evaluations as it delineates the true 
costs of an intervention or program (Creese & Parker 1994).   
Before interventions or programs are considered, their costs need to be measured and 
quantified. One may find that an intervention may be very effective in terms of producing the 
best outcome yet on the other hand it is not affordable. Knowing the costs of an intervention 
allows us to compare interventions and be able to decide which one amongst the many will 
benefit everyone within a reasonable budget (cost effective). Cost estimates are also 
important in determining the feasibility of conducting the intervention or its scale up. Without 
a cost estimate, it is almost impossible to upscale or even implement a similar intervention 
elsewhere. We will discuss the various elements of a cost analysis and the issues around cost 
analysis below. 
11.3.1 Financial versus economic costs  
Costs are made of 2 components: amount of resources used (q) and the unit cost or prices (p) 
(Hutton, Baltussen 2005). Financial costs refer to the actual monetary value of the inputs 
consumed to produce a good or provision of a service (Walker, Kumaranayake 2002). 
Economic costs represent the value of the next best alternative foregone (opportunity cost) 
as a result of the use of resources (Drummond et al. 2005). An example of an economic 
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cost is voluntary labour. This is because voluntary labour in an intervention may have a 
monetary value of 0 (financial cost) yet the volunteers who opted to provide the service 
could have been doing something else (i.e. farming) in the community that could have 
benefited the society (opportunity cost). Economic costs thus include all resources that 
were used in an intervention even if they were provided for free (i.e. donated goods).  
 
11.3.2 Direct, Indirect and Intangible Costs 
The three types of costs that are considered when doing a cost analysis are: direct, indirect 
and intangible costs (see table 4). Direct medical costs are the health care resources that are 
used to deliver the health intervention and can be incurred by either the patients or the 
provider of the health service (see section 2.2 on the perspective of the analysis) (Weinstein 
et al. 1996). From a patient perspective, direct costs refer to out of pocket payments made by 
patients while seeking care (Meheus et al. 2006, World Health Organization 2009. Direct 
costs can be classified as either medical (DMC) or non-medical (DNMC) related costs 
(Tarricone 2006). Direct medical costs include for instance medicines, laboratory tests, health 
care personnel, supplies and overheads. Direct non-medical costs consist of non-medical 
goods and services such as transport cost and food costs.  
Who bears direct costs may vary based on who is providing the service. In countries 
where primary health care services are provided free of charge at public hospitals (i.e. South 
Africa), direct costs borne by the patients are different from those who do not have free 
access. An example of a direct medical cost is “drug cost” which are borne by the patient if 
services are not provided for free, yet when the service is for free then it’s a direct cost from 
the providers point of view.   
Indirect costs refer to the productivity losses incurred by patients or households 
because of not being able to work due to an illness or loss in economic productivity due to 
death (Weinstein et al., 1996) and in accounting, indirect costs refer to overhead costs that are 
shared amongst departments (Tarricone 2006). In this section when we say indirect costs we 
are referring to productivity losses. Indirect costs may also include the reduced ability to 
enjoy leisure due to morbidity or unrelated future health care cost. Income losses due to the 
inability to work or enjoy leisure time due to morbidity are considered a productivity losses 
(Liljas 1998).  
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Different methods are used to estimate the productivity losses and these include: the 
human capital approach and the friction cost method. The most commonly used method in 
economic evaluations to estimate productivity losses is the HCA (Liljas 1998). Using the 
human capital approach, indirect costs are estimated by calculating the reduction in future 
income as a result of mortality or morbidity (i.e. loss of income) (Weisbrod 1961).  For 
example, to estimate productivity losses using HCA, the number of hours lost are multiplied 
by the hourly wage rate.  The Friction cost approach considers the number of hours lost 
before an absent employee is replaced (Koopmanschap et al. 1995). The period where the 
employee is unavailable/absent before someone else takes over is called the friction period.  
HCA takes the patients perspective by considering the number of hours that the patient is not 
able to work as lost income while the friction cost method only considers the number of hours 
lost before another employee takes over their role or a replacement is made for those duties 
van den Hout 2010, Koopmanschap et al. 1995).   
The final category of costs are the intangible costs. These represent the cost of e.g. 
pain and suffering; however, they are usually not taken in to account because of the difficulty 
of valuing these and will not be discussed here (Creese, Parker 1994, Weinstein et al. 1996). 
Table 4: Examples of direct and indirect costs 
 Perspective 
 Patient  Provider Societal 
Hypertension related 
cost 
   











Food costs (bought at the 
facility) 
Travel costs 
 Food costs (bought at the 
facility) 
Travel costs 
Indirect Costs Income loss 
Loss of leisure time 
 Income loss 
Loss of leisure time 
1We considered direct costs within the context of South Africa where patients do not have   
direct medical costs at public health care facilities. 
11.3.3 Capital Costs versus Recurrent Costs 
Costs can also be classified as either recurrent or capital costs based on their working life and 
value (Drummond et al. 2005. Resources that are purchased once over a long period of time 
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(i.e. more than a year) and have a value of more than $100 are referred to as capital costs. 
Examples of capital costs include buildings, vehicles, initial service training, furniture and 
equipment. Resources that are regularly purchased and have a working life of less than are 
year are referred to as recurrent costs (Creese, Parker 1994). Examples of recurrent costs 
include; salaries, rates, drugs and electricity. Equipment that has a lifespan of over a year but 
with a value of less than $100 are also considered recurrent costs. Equipment valued less than 
$100 but with a lifespan of over a year is also considered recurrent (Wonderling 2011).  
11.4 Discounting 
Discounting is used by researchers to adjust future outcomes and costs to the present time 
(Walker & Kumaranayake 2002). By applying discounting, you calculate the present value of 
all future outcomes and costs. Costs have different values when looked at from different time 
periods. People place different values to resources based on the time that they will receive the 
benefit (Drummond et al. 2005).  Drummond et al explains that this time preference often 
biases people perceptions on the interventions to prioritise. Because costs and outcomes 
occur at different time periods, people tend to focus more on the treatment programs as 
compared to prevention programs. Individuals would rather have the benefits now and pay in 
the future.  To account for this time preference, discounting is used to adjust future costs and 
future outcomes. A discount rate of between 3 to 5% is normally used by most researchers 
(Meheus et al. 2013, Hansen et al. 2000, Settumba et al. 2015). Where there is no specific 
discount rate imposed for discounting, any discount rate can be used as long as a sensitivity 
analysis is done at different rates for comparability with other studies. Discounting future and 
present costs using interest rates to represent the opportunity costs of using the money now as 
compared to the future use is relatively accepted. However discounting outcomes on the other 
hand is controversial as it might not be the case that people value health less in the future than 
they do in the present. 
11.5 Approaches to Costing 
A cost analysis comprises of three stages that include identification, quantification and 
valuation (Creese, Parker 1994). Identification is the first stage of a cost analysis whereby all 
the resources that were consumed while providing a service or intervention are 
comprehensively identified and listed. The identification process is guided by the perspective 
of the study which determines the frame of costs (and outcomes) to include (Raftery 2000). 
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Depending on the purpose and reason for the cost analysis, only costs that are of interest are 
considered. For example, if an intervention is intended to better patients’ lives, the patient 
would want to know how the introduction of such an intervention affects them and in such a 
case taking a patient perspective is important. 
Quantification refers to the process of determining how much was used for each 
resource change in terms of quantity. This process of quantification is based on the 
differences in resource usage between interventions. For example, if a trial using mobile 
phones was conducted to reduce blood pressure over a twelve-month period, the difference in 
resource usage between the trial and the usual care is used to quantify the resources used in 
the trial for that period. 
Valuation refers to the process of assigning a unit cost to each resource that was 
consumed during the provision of an intervention or service as well as determining the total 
costs for each category of resources that were utilised. Total cost is determined by 
multiplying the unit costs of an intervention by the total number of the resources used which 
in turn yield outcomes such as cost per mmHg reduction in blood pressure. Unit costs of 
resources are not always readily available and sometimes even the costs that are available 
may not reflect the true cost to the society (Weinstein et al. 1996). To value resources, 
researchers make use of either gross costing or micro costing. 
Gross costing refers to the process where researchers allocate a total budget that is 
readily available to a group of services that are being provided such as outpatient visits (top 
down approach) (Raftery 2000). Gross costing is a more aggregate technique. Based on the 
data of resource use available, the unit cost of an event is calculated by obtaining an average 
cost based on usage. For example, if gross costing is used to calculate the cost per 
hypertension visit at a facility, the total resource cost by hypertension patients for that period 
will simply be divided by the total number of hypertension visits. It is often used when 
costing program of interventions where very large resources are used.  Step down approach is 
a gross costing technique which involves the allocation of expenditure to departments of 
interest in a step wise fashion. Micro-costing on the other hand is a more detailed approach 
which involves the collection of detailed measurements of resources used by an intervention 
or program to provide services Micro costing is time consuming because it is a very detailed 
method. Researchers must list down every item that was used before assigning them a cost 
(bottom-up costing or ingredients approach). The unavailability of data in low and middle-
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income countries makes micro costing difficult or often not feasible, and researchers 
therefore use less precise methods or combinations of methods such as top-down and bottom-
up costing.  
A combination of the ingredients approach and the top down approach is increasingly 
being used to cost an intervention (Hansen et al. 2000, Meheus et al. 2013, Settumba et al. 
2015). In this approach, the hotel cost which is the cost related to the average resource use is 
separated from the direct medical care costs (Drummond et al. 2005).  The top down method 
is used to estimate the hotel cost and the ingredients approach is used to estimate the medical 
costs.  This approach offers the most appropriate valuation as the general average cost related 
to the indirect cost is combined with the medical direct cost that is directly attributable to the 
condition or medical intervention.  
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12 Empirical Review  
12.1 Cost and cost-effectiveness studies in mHealth 
As the use mobile technology within the health sector increases, it is important that all 
aspects related to the mHealth interventions are looked at. To date, they are a lot of efficacy 
and acceptability studies conducted with very limited economic evaluation studies on 
mHealth that address both the cost and the outcome side of those interventions. The scarcity 
of resources in the health sector makes it particularly important that only interventions that 
are both cost effective and efficient are implemented.   In this section, we will review 
economic evaluations studies that have been conducted in mHealth interventions.  A 
summary synthesis of the mHealth economic evaluation studies that were used for this part of 
the literature review if provided in table 5 
12.1.1 Economic Evaluation of mHealth 
Several methods are used to conduct economic evaluations in mHealth studies across 
different diseases and countries. Regardless of the type of economic evaluation that is 
conducted, a cost analysis forms the first part of the economic evaluation. In a cost analysis, 
the costs of all resources consumed by the intervention to produce an outcome are estimated. 
Costing an mHealth intervention is dependent on several factors which include the 
perspective, type of costs and most of all, the entity interested in the costs. A combination of 
methods is often used to fully analyse the cost of mHealth interventions as one method of 
analysis may not be sufficient to capture all the elements of resources sufficiently.  Below we 
look at economic evaluation studies that were conducted in mHealth. 
Chang et al (2013) conducted a cost analysis to estimate the cost of resources that 
were used to provide a peer health worker supported intervention and a mobile health 
supported intervention to improve AIDS care in Uganda using a retrospective analytic 
technique. The ingredients approach and step-down costing methodology was used even 
though not explicitly specified in the article. The ingredients approach was used to estimate 
the intervention costs through the aggregation of the all the inputs (the ingredients) utilised in 
the program before assigning a unit cost to each item in-order to get the total costs of the 
intervention. From the total cost, the average unit cost was determined based on the number 
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of people served or the number of service output provided (Creese & Parker 1994). The study 
focussed on recurrent costs and not on capital costs such as buildings and furniture. The 
seven steps suggested by Conteh et al (2004) were followed while doing the cost analysis and 
the mHealth intervention was found to produce an additional yearly cost of $2.35 per patient. 
The seven steps include (1) defining the final product (2) defining the cost departments (3) 
identifying the full costs of each input (4) assigning inputs to cost centres (5) allocating all 
costs to the final cost departments (6) computing the total and unit costs for each department 
and (7) reporting the results (Conteh & Walker 2004). 
A study by Larsen-Cooper et al (2015) in Malawi, assessed the cost per user and cost 
per contact per user of an mHealth intervention in maternal, new-born and child health. They 
made use of a base cost model to estimate the unit costs of the intervention. Recurrent costs 
and capital costs were considered in their analysis and costs that they felt were not necessary 
should the program be scaled up where left out (i.e. costs that were associated with the pilot 
studies such as international travel and staff time). This is in alignment with other studies that 
also leave out costs of resources related to the pilot studies when conducting a cost analysis 
(Chang et al. 2013). The rationale being that these are one-time costs (sunk costs) that are 
related to the development and perfection of the intervention (developmental costs) which 
would however not be incurred again should the intervention be implemented elsewhere. 
Rodrigues et al (2014) conducted a study in India to assess how much it would cost 
the Indian National AIDS Control Programme to implement a mobile intervention to support 
adherence to antiretroviral therapy in Karnataka State. One-time costs and recurrent costs 
were considered to cost the intervention. The authors used the concept of avoidable costs 
where costs that are only incurred once but not incurred again if the intervention is 
implemented are left out (i.e. developmental costs) (Rodrigues et al. 2014).  A sequential 
costing methodology where resources are identified in their natural units, quantified, assigned 
a unit cost which subsequently gets used to determine the total cost was used.  The cost was 
determined at national programme level as well as at ART-centre level. The intervention was 
found to costs between USD1.27-USD1.77 per patient per year depending on the type of 
reminder, number of ART patients and the total number of functioning ART centres. The cost 
of the mHealth intervention was found to be of low cost and it improved patient adherence 
plus it could be implemented at low cost in the country (Rodrigues et al. 2014). 
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Zurovac et al (2012) conducted a cost and cost effectiveness analysis of using an mHealth 
intervention to improve adherence to malaria guidelines in Kenya. The programme was 
aimed at the health workers to ensure that they follow the Malaria guidelines by sending them 
text messages on their mobile phones regularly. The cost analysis was conducted to assess the 
cost of the mHealth interventions across three different scenarios; under the trial conditions, 
if implemented by the ministry of health and lastly if the intervention was expanded to a 
national scale in Kenya.  The costs per additional child correctly managed were highest under 
study conditions (0.5USD), 0.36 USD under the ministry of health and lowest (0.03) if 
implemented nationally. The difference in cost per additional child varied since the resources 
considered for the cost analysis in the different scenarios differed.  
The reduction in the unit cost per intervention as the program gets up-scaled is 
normal.  Considering the learning curve effect, it is often the case that to produce the same 
amount of output, the amount of resources that are required decrease with time and especially 
when the program is conducted on a larger scale the average long run average costs decrease 
substantially because of improved technical efficiency (Mogyorosy & Smith 2005). Zurovac 
et al (2012) did not consider the capital costs such as buildings where the service is being 
provided but rather focused on the developmental costs and other intervention specific costs 
related to the programmes implementation and running.  Their results show that the major 
cost contributor of the programme differs depending on the purpose of the programme. 
Developmental costs were the largest under the study trial conditions when compared to the 
other scenarios.  
Depending on the reason of the cost analysis, developmental costs of an intervention 
may be important if for example the reason of the analysis was to find out how much the 
intervention costs to develop (Drummond et al. 2005, Mogyorosy, Smith 2005). Apart from 
developmental costs, the other cost categories considered in mHealth economic evaluations 
are; the human resources and management costs, developmental costs, operational and 
maintenance costs of the intervention, training costs and governance costs (Agarwal et al. 
2016). Human resources and management refers to the frontline workers that are responsible 
for making sure that the interventions run as they are involved in the day to day activities if 
the intervention. Operational and maintenance cost refer to resources that are used by the 
intervention daily such as text messaging costs, airtime costs, internet costs and the cost of 
electricity among other things. Training costs refer to the initial preparation of material that is 
used to teach the frontline workers how the intervention will be run. Training may be a once 
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of thing but depending on the type of intervention, it may also be ongoing. Lastly governance 
costs as described by Agarwal et al (2016) refer to the costs associated with the decision-
making process by policy makers and the government regarding the intervention.   
Not all cost categories are considered by researchers while doing their analysis. Some 
researchers include developmental costs in their analysis (Zurovac et al. 2012) yet some 
researchers consider them onetime costs that would otherwise not be experienced should the 
intervention be implemented elsewhere and thus leave them out (Chang et al. 2013). 
Equipment cost and operational costs such as airtime usage and cost of text messages are the 
most readily available information that is analysed by almost all the researchers doing a cost 
analysis in mHealth (Chang et al. 2013, Larsen-Cooper et al. 2015, Mogyorosy, Smith 2005, 
Rodrigues et al. 2014). Training costs are considered in some studies and in other studies they 
are left out. The issue is that there is no set standard of doing a cost analysis which defines 
how they are to be done or which metrics to use so that the results of the different studies are 
comparable. The costing strategy and methodology used in a way also dictates which cost 
categories to use and which ones to leave out. Micro costing methodology was used to cost 
most mHealth interventions in most cost effectiveness analysis of mHealth studies. The 
costing strategy used by Larsen-Cooper et al. (2015) included making a list of the essential 
programme resources and their quantities before assigning the cost of each item and getting 
the total amount for the programme; the ingredients approach. The ingredients approach was 
used in almost all the mHealth cost effectiveness studies analysed (Chang et al. 2013, Larsen-
Cooper et al. 2015, Mogyorosy, Smith 2005, Rodrigues et al. 2014). Despite using similar 
costing techniques, the perspective of the study also determines which cost categories to 
include in the analysis. The next section looks at how the different perspectives were used the 
mHealth economic evaluation studies. 
12.1.2 Cost Perspectives 
The cost perspectives considered while doing a cost analysis are the provider perspective, the 
patient perspective and the societal perspective (see section 11.2). The provider perspective, 
sometimes referred to as the health system perspective or implementer perspective was the 
most commonly used perspective in mHealth economic evaluation studies. Zurovac et al 
(2012) used the provider perspective to consider the costs of the intervention at different 
implementation levels which were; study level, under ministry of health as the same sites and 
at national level.  Using the provider perspective helps the program researchers and policy 
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makers know the costs of conducting the program at trial level as well as at national level. 
The disadvantage of using this perspective only is that it does not consider costs borne by the 
people at the receiving end of the intervention. Thus, the intervention may be cost effective 
from one perspective (provider perspective) whereas from another perspective (patient 
perspective) it might not be the case. For each intervention, costs are not solely borne by the 
providers only but also the costs are borne by the recipients of the mHealth intervention.  The 
entities providing the intervention may only consider costs that only concern them and not 
worry about the other costs that may affect the other parties. Since economic evaluations are 
based on welfare economics, the societal perspective is the ideal perspective as it would 
consider the welfare of every party involved (Mogyorosy, Smith 2005). The societal 
perspective provides a more comprehensive view of the mHealth provision and 
implementation as it would encapsulate all the costs involved, regardless of who is funding 
the program. In the next section, we look at the type of costs that were used in the studies. 
Often the perspective and type of costs used in a cost analysis are based on the reason of the 
analysis and the entity interested in the results of the analysis. 
12.1.3 Type of costs and cost categories 
All the studies made use of financial costs to determine the cost of the mobile health 
intervention (Chang et al. 2013, Larsen-Cooper et al. 2015, Mogyorosy, Smith 2005, 
Rodrigues et al. 2014). As mentioned is section 11.3.1, financial costs analyse the actual 
monetary cost of the resources that have a monetary payment.  If the aim of a cost analysis is 
to determine the cost of the program to the study managers and facilitators, financial costs are 
important to them as they show the actual amount of money that was used to pay for the 
intervention. However, when costing an intervention that has a possibility of being 
implemented elsewhere, economic costs should also be considered. In mHealth interventions, 
economic costs would be beneficial as they can capture the opportunity costs of resources 
that were used in the intervention. Considering only the financial costs while costing may 
leave out important costs that may be useful in determining the amount of resources required 
for an intervention as well as properly assessing the efficacy and effectiveness of such an 
intervention. It would be advantageous when doing a cost study to report both the financial 
and economic costs of an intervention as done in other cost analysis for other diseases and 
interventions (Conteh et al. 2004). 
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Costs items that are often considered while costing an intervention are those that are 
most likely to be essential when replicating the same intervention elsewhere. This was seen in 
all the cost studies in mHealth as sunk costs were not considered.  Cost items were 
categorised either according to activities or function in the studies. It was common practice to 
first categorise the activities that were exclusive to the intervention and from then, an 
ingredients approach was usually taken to cost the intervention.  The four activities that were 
common across the mHealth interventions costing studies were; development, pilot testing, 
implementation and sustenance. Based on the activity, it was easier to identify the resources 
that were used and then later assigning a cost based on the quantity used. Development is the 
process of the actual development of the intervention. The mHealth development stage 
involves the creation of databases, acquisition of equipment and mobilization of the human 
resources. Pilot testing involves the actual testing of the intervention on a certain number of 
individuals prior to the study being conducted. Implementation involves the actual 
implementation of the programme, either at facility level, study level or even at national 
level. Lastly, sustenance involves the actual process of making sure that the programme runs 
efficiently over a certain period. 
12.1.4 Lessons from the Articles 
A couple of lessons were obtained from the review of the articles. First the results have 
shown that mHealth interventions that use text messaging based platforms are generally 
associated with low incremental costs when compared to the standard care of most diseases. 
The low costs of the text messaging based interventions are a result of the low short 
messaging service (SMS) costs. Depending on the type of mHealth intervention being 
implemented, start-up costs and developmental costs may form the bulk of the costs. Second, 
unit costs of mHealth interventions that made use of text messages may be further reduced 
when interventions are implemented on a larger scale (economies of scale) with improved 
efficiency. Third, cost analysis results are very context specific. We found out that there are a 
lot factors that determine the costs. For example, the cost of mobile phones is different across 
different regions, the costs of sending a text message changes from time to time.  Fourth, the 
importance of a sensitivity analysis in mHealth EEs. Costs are sensitive to many factors and it 
is important to vary those factors. In one study, it was found that the costs of sending a text 
message had changed from the period the mHealth intervention trial was conducted to when 
the EE was conducted (Chang et al. 2013). Because of technological advancements, there is 
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always be a newer mobile phone or system that will affect the price of the previous model. 
Fifth, the use of a standard currency facilitates study comparability. Most of the studies used 
the US$ to standardise costs. The average exchange rate per year is used for the conversion. 
However, costs are very responsive to the trading rates. In countries with political instability 
among other issues, the rate can change overnight and drastically affect the cost per unit. 
Lastly, the importance of using a checklist to improve transparency and rigour. Using the 
WHO outcome measures, mHealth interventions in hypertension should ensure efficiency, 
effectiveness accessibility, acceptability, safety and equity across the whole population before 
they can be considered for up scaling (Peiris et al. 2014).  
With a lot of studies on mHealth in chronic diseases allegedly being of low standards 
and a few of high quality, it is hard to say whether the use of mHealth in hypertension is 
beneficial (Peiris et al. 2014). This is because previously there was no standard of reporting 
the evidence of the mHealth studies. Recently a team at the WHO published a 14-item 
checklist which they called mobile health evidence reporting and assessment (mERA) 
checklist that should be followed when reporting mHealth studies to ensure transparent and 
rigorous evidence (Agarwal et al. 2016). Item number 9 on the mERA checklist speaks to the 
inclusion of the cost of the mHealth intervention while reporting the findings. Without the 
costs of an intervention, it is almost impossible to determine the benefit of the intervention. In 









Objectives & Perspective Issue of 
focus 
Strategies used to 
measure the costs and 
cost effectiveness of 
mHealth. 








-to assess the costs of 
implementing a mobile phone 
reminder to support 
adherence in ART therapy 
-Provider Perspective 
- cost of 
mHealth 
-used the concept of 
avoidable costs (did not 
consider sunk costs in the 
analysis) 
-measured onetime costs 
(equipment), and 





- It would cost between 
USD (1.27 - 1.77) per 
patient per year depending 
on the type of intervention 
-the total cost of mHealth 
intervention in India is low 
-the low cost of telephone 
services and the use of free 
software’s in LMICs may 
result in a lower cost of the 
intervention. 
-Potential to improve 
adherence and reduce the 
number of people to use 
second line treatment. 
-Over a 5-year period, the 
intervention was estimated 
-the use of mobile phones 
may leave out the poor, 
illiterate and uneducated as 
they might not have phones 
-potential for disclosure of 
private information if 
intercepted by others i.e. 
HIV status 
-costs of the intervention 
are sensitive to currency 
exchange rates. 
-costs may differ depending 
on the provider. 
-Text messages and call 
rates change over time. 
-Costs very sensible to the 
context (i.e. Number and 
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to account for 0.36% of the 
total national budget.  






- to perform a cost analysis of 
the Peer Health Workers and 
mHealth SMS Interventions 
used by the PHWs 








-Unit costs determined 
by the actual amount 
used (financial costs) 
-used a threshold analysis 
to assess potential 
intervention cost savings. 
-Cost categories 
considered for mHealth-
startup, training, and 
maintenance costs. 
-PHW cost per patient 
$8.74 and $2.35 for 
mHealth 
-PHW and mHealth 
intervention averts more 
than 1.5 future second line 
switches in ART and thus 
cost saving 
-The threshold analysis 
used a means to 
contextualize the results 
-costs found to be 
affordable 
-limitations-possibility of 
task shifting between the 
interventions which may 
prevent the accurate 
measurement of the 
individual intervention 
costs 
-further research in 
implementing these types 
of interventions in complex 
economic models 
-the costs of mobile 
phones, airtime varied a big 
deal (significant change 
from when the trial was 
conducted and when the 





calculated total costs with 
and without staff costs 
MHealth-airtime costs, 




-evaluate costs and cost 
effectiveness of a mobile 
phone text message reminder 
program to improve 
adherence to Malaria 
guidelines under three 
implementation scenarios 
(study conditions, ministry of 






-Used Financial costs. 
-used financial records 





distribution system, cost 
of collecting HWs 
mobile numbers and 
Implementation cost. 
-45% of the costs under 
study conditions were used 
to develop and pretest the 
text messages while the 
cost of developing the text 
messages accounted for 
12% of the costs. 
- Costs per additional child 
managed under study 
conditions was $0.50, 
under Ministry of Health 
$0.36 and 0.03 if 
implemented nationally. 
-SMS intervention found to 
be effective and 
inexpensive 
-the SMS sent to health 
-future research to optimize 
delivery, find out the 
reasonable SMS frequency 
and duration of the 
intervention. 
- The opportunity cost of 
sending SMS in the facility 
- Development of a text 
messaging intervention 
addressing integrated 





management and different 
diagnostic tests posed the 
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workers to optimize 
adherence to treatment 
guidelines. 
-cost of the intervention per
additionally managed child 
under study conditions 
were higher but low when 
included in routine 
practice. 
-Intervention cost on
national scale represent 1% 
of the allocated money for 
malaria treatment. 
-intervention can be seen as
a complement and not a 
replacement. 
total costs to be higher for 
each scenario. 
-cost per additional child
correctly managed 





-to determine cost per user
and cost per contact with 
users of an mHealth 




-used a base cost model
-selected capital and
recurrent costs were 
used. 
-Cost data from financial
-intervention cost $29.33
per user and $4.33 per 
successful contact. 
-Sensitivity analysis
showed a possible 48% 
Sensitivity analysis- varied 
the utilization of the 
various intervention in the 
study hence the total costs 





-Programmatic Perspective records, service level 
agreements and the 
program budget 
-financial costs used 








techno related fees, travel 
and transport costs. 
-only capital costs 
needed to replicate the 
service used. 
 
improved if the service 
were to operate at full 
capacity. 
- domestic management 
and oversight 285 of the 
total intervention costs, 
administration fees 7 % tips 
and reminders also 7% and 
capital costs only 4%.  
Labor costs contributed 
52.5% of the total costs of 
the intervention. 
implementation scenarios. 
-Costs dependent on 
utilization thus hotline 
costs varied in certain 
periods. 
-total programmatic costs 
could not be disaggregated 
to service type, multiple 
outcomes not accounted for 
in other individuals, 
exclusion of volunteer 
time. 
-Future research-monetize 
benefits and use BCA for 
easy comparison,  
- consider costs and cost 




12.2 Cost of Illness Studies on Hypertension 
12.2.1 Summary of results 
Most studies on the cost of hypertension have been conducted in middle- and high-income 
countries, with very few studies done in low-income countries as summarized in Table 6. 
Evidence reported in these studies shows that hypertension management is costly, making it 
both a health and an economic burden. The cost of hypertension care varied from country to 
country, with the United States of America (USA) having the highest cost of care while 
Nigeria had the lowest cost of care. In the USA, annual direct expenditure of hypertension 
was as high as US$54.0 billion (Balu & Thomas, 2006). High-income countries have the 
highest unit cost of care, followed firstly by middle-income countries, and lastly by low-
income countries.  
Regardless of the unit cost of care, the economic impact of hypertension care is huge 
in all countries. The high cost of care for hypertension subjected many patients residing in the 
south-western part of China to catastrophic payments. 8.9% of the population experienced 
catastrophic payments and 4.1% of those households became impoverished after paying the 
hypertension costs (Le et al., 2012). In Nigeria, hypertension costs led to a 52.8% incidence 
of catastrophic payments among the study population (Ilesanmi, Ige & Adebiyi, 2013). A 
catastrophic payment occurs when a household uses more than 10% of its total household 
income on healthcare (in this case, hypertension costs) (O'Donnell et al. 2008). 
Impoverishment refers to the percentage of the population that drops below the poverty line 
after paying healthcare costs (Mills et al., 2012). In 2010, the annual costs of hypertension 
care in Brazil were so high that the annual costs represented 0.08% of the country’s Gross 
Domestic Product (GDP) (Dib, Riera & Ferraz, 2010). Considering that the total healthcare 
expenditure as a percentage of GDP for Brazil was 7.6%, hypertension posed a very huge 
economic burden, as it accounted for merely 1.1% of that 7.6% in that year.    
Looking at the drivers of hypertension costs, the major drivers in most cases are anti-
hypertensive drugs (Nguyen et al., 2014; Le et al., 2012; Al-Efan, 2009), except when the 
study includes hospital care costs (Nguyen et al., 2014). In some instances, antihypertensive 
drugs were attributable to up to 80% of the total cost of hypertension care (Maetzel et al., 
2004). Also, as the number of antihypertensive drugs per patient increases, so does the cost of 
care (Al-Efan, 2009). Different regions use different first-line antihypertensive drugs for 
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hypertension management. In most studies, diuretics were the first-line treatment (Ganiyu & 
Suleiman, 2014; Costa, Juvenal Soares Dias da et al., 2002), while in other countries, like 
Bulgaria and Serbia, the first-line drugs were angiotensin-converting-enzyme inhibitors (ACE 
inhibitors), followed by treatment with calcium-channel blockers (Ivanova et al., 2009). 
Diuretics and the use of no more than 2 antihypertensive drugs per person were found to be 
cost-effective (Ganiyu & Suleiman, 2014; Costa, Juvenal Soares Dias da et al., 2002). In 
addition, the presence of co-morbidities and the severity of hypertension affects the cost of 
hypertension care. Co-morbidities have a significant influence on the total cost of 
hypertension management (Maetzel et al., 2004).  The cost of care for patients with advanced 
hypertension or for those with comorbid diseases is higher than for those with primary 
hypertension alone (Ilesanmi, Ige & Adebiyi, 2013). A study by Nguyen et al. (2014) 
indicated that the total cost of hypertension care on its own in Vietnam was lower than the 
total cost of hypertension care among individuals with both hypertension and 
hyperlipidaemia. 
12.2.2 Findings and Lessons from the Studies: cost of illness studies 
Assessing the cost of care in a disease-specific cost study is dependent on the costing 
methodology used, the type of study conducted and the perspective that is taken in the study. 
Most costing studies shown in Table 6 were cross-sectional studies.  Cross-sectional in the 
sense that data collection and analysis for a certain population or subgroup was done at a 
specific point in time. Different perspectives (patient, provider and societal) were taken to 
analyse the cost of care. The provider perspective is used by researchers when they are 
interested in the costs borne by the provider (Nguyen et al., 2014). Provider costs include 
both the direct and indirect costs of providing a service. The provider costs include drug 
costs, consultation fees, laboratory tests, health workers’ salaries and so on (Drummond et al., 
2005), and are usually captured through the assessments of patient files and cases (Nguyen et 
al., 2014; Ivanova et al., 2009). Some studies took the patient perspective, concentrating on 
the costs borne by the patients themselves (Ilesanmi, Ige & Adebiyi, 2013; Maetzel et al., 
2004). The common costs assessed included travel costs, consultation fees, admission fees, 
indirect costs and laboratory costs. 
Some studies focused on all direct medical-care costs, meaning that they considered 
both the direct medical-care costs and the direct non-medical-care costs associated with the 
disease (Le et al., 2012). An example of a direct medical-care cost is drug cost, while 
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examples of direct non-medical-care costs include administration and transport costs. Other 
studies focused only on the direct costs of drugs that were utilised by different patients 
(Ganiyu & Suleiman, 2014; Ivanova et al., 2009). This difference alone results in differences 
in the cost of care, even within the same region.   
Inconsistencies in the inclusion of and estimation methods for indirect costs of care 
were also seen among the different papers. Indirect costs refer to the best forgone use of time 
and are measured as the loss of income to the individual or to the household (Drummond et 
al., 2005; Creese & Parker, 1994). From a provider perspective, these can be the average 
resource use per visit, while, from a patient perspective, they could refer to the opportunity 
cost of being at the facility (i.e. lost income or lost time). If costing studies use different 
methodologies, the costs of care measured will differ and, most importantly, the results will 
not be comparable. 
Some costing studies are incomparable for many reasons. These reasons include 
inconsistent methodology. Some researchers make use of secondary data sets to draw up their 
costing data (Balu & Thomas, 2006), while others make use of study tools like questionnaires 
(Le et al., 2012; Al-Efan, 2009). Even the perspective taken differs with each study, with 
some deciding to use the patient perspective, some using the provider perspective and others 
using the societal perspective. Since there are currently no set rules of conducting a cost 
analysis, the costs measured will always differ and comparisons between studies will be 
difficult. The societal perspective is the most comprehensive way of doing a disease-specific 
study as it captures all the costs involved (Drummond et al., 2005). Looking at table 6, 
costing studies are also presented in different currencies and periods. The results are 
presented as a monthly cost, an annual cost or, sometimes, as an incremental cost. This makes 
comparing the results among countries difficult, especially if the results are presented in 
different currencies. Regardless of all these issues, all costing studies on hypertension cost 
show that the cost of care is high. 
Despite the high cost of care and various methodologies for costing, hypertension on its 
own is generally undermanaged, with a small percentage of the patients achieving the 
required blood pressures. For example, in a study by Ilesanmi et al., (2013), only 33.6% of 
the study population achieved the desired blood pressure, owing to non-persistence and non-
adherence to medication. In South Africa, more than 50% of people who are on 
antihypertensive medication have uncontrolled hypertension (Carter, Bosworth & Green, 
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2012). Most people with hypertension in South Africa have uncontrolled hypertension (Steyn 
et al., 1999). As an initiative to control and manage hypertension in South Africa, several 
models of care have been implemented in the republic. Addressing medication adherence 
being one of the major areas being target. One such model of care is the use of text 
messaging based interventions and other mHealth programs.  
12.3 Conclusion 
In this literature review we looked at economic evaluation studies in mHealth and the cost of 
illness studies in hypertension. MHealth interventions in most cases were found to be cost 
saving in the long run when upscaled despite having a high initiation cost. With the rapid 
advancements in mobile technology, the cost of using such interventions will decrease with 
time. For example, the price of text messages in the last ten years has gone down in South 
Africa. Text messages (operational cost) being one of the major cost drivers of mHealth 
costs, any reduction in the price is welcome. Partnerships with other sectors (i.e. NGOs and 
private sector) and the government to provide efficient mHealth interventions may further 
reduce their average costs as they are shared among the different sectors, after all the 
interventions have the potential to benefit everyone.  
Looking at the cost of illness studies in hypertension, drug costs were found to be the 
major cost driver followed by consultation costs. However, in countries where primary health 
care services are provided for free, patients are faced with direct nonmedical costs and 
indirect costs such as transportation costs and lost income. In some instances, the patient 
costs had the potential to become catastrophic and possibly impoverish households.  
Considering that hypertension is a chronic disease with no cure, patients costs are always 
going to be there and it is thus important to know how much they are and how they affect 
households.  
The literature shows to date that there has been no cost study done to assess the cost 
of hypertension care in South Africa. There is currently no research on the cost and cost-
effectiveness of mHealth interventions for the management of hypertension in South Africa. 
This research is needed on the one hand to assess the feasibility and affordability of 
implementing these interventions, and on the other hand to compare mHealth interventions 
with alternative uses of resources through cost-effectiveness studies.  
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Table 6: Summary of Hypertension Costing Articles 
Study Author(s) Country Study Type and Data 
extraction tools 
Costs Measured Perspective Hypertension costs 
(Ganiyu, Suleiman 
2014) 




Average monthly cost per: 
• Diuretics= NGN858.6 ($5.51)
• Blockers a= NGN1101.1
($7.07)
• Fixed dose combinations =
NGN10 425. ($66.93).





• Indirect • Patient
Annual cost US$3900 









Mean unit cost of illness $9393.3 
(Costa, Juvenal 
Soares Dias da et 
al. 2002) 




• Indirect • Patient







• Secondary data • Direct
Total incremental annual direct  
 Expenditure= $US 54.0 billion  
Mean incremental annual direct 
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Study Author(s) Country Study Type and Data 
extraction tools 
Costs Measured Perspective Hypertension costs 
expenditures per individual = $US 
1,131. 
 
(Nguyen et al. 
2014) 
Vietnam Retrospective survey 
• Financial records 
• Direct 
 
• Provider Median total direct costs per patient 
= US$65 
(Dib, Riera & 
Ferraz 2010) 
Brazil  • Direct  Estimated direct annual cost in: 
Public health system= US$ 398.9 
million 
Private health system =US$ 272.7  
(Ilesanmi, Ige & 
Adebiyi 2013) 
Nigeria Cross-sectional survey 
• Chat Review 
 
• Direct (drug 
costs) 
• Indirect 
• Patient Mean cost of treatment $9.6 
Median monthly drug cost $6 
(Al-Efan 2009) Malaysia Prevalence-based and 
incidence-based cross-sectional 
study. 






Patient The total costs for pre-
hypertensive, stage 1 and stage 2 
• Direct costs:  RM1612.38, 
RM1741.85 and 
RM2718.21   




Study Author(s) Country Study Type and Data 
extraction tools 
Costs Measured Perspective Hypertension costs 
RM7511.41 




 • Direct (drug 
costs) 
Provider Monthly cost of hypertension  
• Serbia = 12.56 Euro  
• Bulgaria= 8.23 Euro  
Monthly cost for complicated 
hypertension  
• Serbia 13.39 Euro  
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The cost and cost-effectiveness of a text-messaging 
based intervention to support management of 




Background: The consequences of uncontrolled hypertension are increasingly becoming an 
economic burden both to the public and the government. Non-adherence to medication is one 
of the factors contributing to poor blood pressure control. Several strategies have been 
studied to improve adherence to blood pressure lowering treatments, including mobile-phone 
based health interventions such as sending text-messages targeting support and behaviour 
change. The objective of this study was to examine the cost and cost-effectiveness of a text-
messaging based intervention to support management of hypertension within the context of a 
text-messaging based intervention (the SMS-text Adherence suppoRt trial, StAR*-BP) 
conducted in an urban public-sector clinic in Cape Town. 
Methods: A combination of the bottom-up approach and step-down costing was used to 
estimate the cost of treatment a health system perspective. One-way univariate sensitivity 
analysis was conducted to deal with uncertainty. All costs were estimated in 2016 South 
African Rand and discounted at 5%. The cost data and the StAR*-BP interventions main 
outcome; blood pressure reduction (expressed in mm HG) were combined to estimate the 
cost-effectiveness of the intervention. A total of 250 patient interviews were undertaken to 
estimate the cost from the patient perspective. 
Results: The primary outcomes were the average cost of blood pressure lowering care and 
the incremental cost of the text-message based adherence intervention, compared to usual 
care, per millimetre of mercury (mmHg) reduction in systolic blood pressure. The average 
health system cost for hypertension care was R262 per visit and patient cost was R172 per 
visit. The incremental cost of the text-messaging based intervention cost was R4 per month. 
The incremental cost-effectiveness ratio of the intervention was R22 per mmHg reduction 
over the twelve-month period. 
Conclusions: 
This is the first study to estimate of the societal cost of hypertension management in an urban 
South African environment and it demonstrates that a text messaging based intervention to 
improve hypertension treatment adherence in South Africa can provide good value for money 
at an incremental cost of R49 per patient per year and an incremental cost effectiveness of 
R22 per mmHg reduction in systolic blood pressure. Our findings support ongoing efforts by 
the Department of Health to study and invest in mHealth solutions that can improve patient 
94 
 
adherence and quality of care. Given the importance of hypertension as a risk factor for 
premature death and disability among South African adults, there is urgent need for research 
on mHealth for cardiovascular disease prevention and care.  
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Between 2001 and 2010, the hypertension prevalence rate among South African adults aged 
25 years and older rose from 24% to 40% (1,2).  This is a concern since, raised blood 
pressure/hypertension is the most important modifiable biological risk factor for 
cardiovascular diseases (CVD) (1,3). Uncontrolled high blood pressure and its sequelae (i.e. 
CVDs such as stroke, heart failure, and ischaemic heart disease) lead to high levels of 
resource use in the health sector as well as loss of human capital due to morbidity and 
premature mortality. Over time, uncontrolled high blood pressure could lead to reduced 
worker productivity, which in turn reduces economic output which may lead to substantial 
reductions in the macro-economic output (GDP) of a country (4). 
 Management of high blood pressure, which is a common condition, consumes a large 
proportion of outpatient care budgets. Because the condition does not usually have symptoms 
and adherence to medical treatment is poor, large investments are required to maintain the 
recommended blood pressure level among affected individuals (5).  Non-adherence to anti-
hypertensive medication on its own is a huge problem as it can lead to ‘difficult-to control 
hypertension’ which substantially increases the risk of developing serious life-threatening 
conditions such as CVDs, strokes and heart attacks (6,7). The effectiveness of blood pressure 
treatment on reducing CVD risk depends on the patients taking their medication consistently, 
usually once to three times daily from the time of diagnosis throughout the rest of their lives. 
Studies have shown that improving medication adherence increases the effectiveness of 
treatment and leads to better patient outcomes(8,9).  Improving adherence may also be cost 
saving by averting the development of CVD. Efforts to monitor medication adherence have 
been made through the use of pill counts, blister packs, text messages and electronic monitors 
(7,10). However, there is no gold standard to monitor or measure non-adherence and it is 
almost impossible to detect intentional non-adherence among patients as none of the 
previously tested methods can show if the medication was taken (10).  
This study focuses on the use of text messages to improve patient adherence to hypertension 
medication. Mobile and wireless technologies (commonly abbreviated as mHealth) such as 
mobile phones are increasingly being used to monitor adherence and improve patient 
outcomes. To date, most studies examining the effectiveness of mHealth have been carried 
out in high-income countries for a wide range of conditions. These studies have generally 
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shown a positive effect, especially when short text-message services (SMS) are used to 
remind patients to take their medication (11).    
In South Africa, a recent randomized trial (the SMS-text Adherence suppoRt trial, StAR-BP) 
investigated the effect of adherence support via Short Message Service (SMS) on blood 
pressure and treatment adherence in adults diagnosed with hypertension and managed in an 
outpatient primary care facility(12). The StAR-BP study, conducted between June 2012 and 
August 2014, allocated participants to one of three groups (arms) that ran in parallel: usual 
care group, information only group and interactive group. Participants allocated to the usual 
care group only received the SMS-texts sent to all trial participants. These messages are sent 
no more frequently than one SMS text-message every four weeks. The messages are a 
welcome SMS text-message, a text confirming enrolment, an SMS text-message on a 
birthday, and other SMS text-messages about participation in the trial.  
Participants allocated to the interactive adherence support received the same messages as the 
information-only group but could also respond to selected messages using free-to-user 
“Please-Call-Me” requests. These generated an automated series of responses from the text-
message delivery system offering trial participants several options including cancelling or 
changing an appointment, and changing the timing and language of the text-messages. The 
information-only adherence support group were sent messages to motivate collecting and 
taking medicines, and to provide education about hypertension and its treatment. Additional 
reminders were sent when medicines were ready for collection or about scheduled clinic 
appointments. All trial participants were given a phone number to contact the research team. 
The trial showed in the information-only intervention arm, compared to the control arm, an 
improvement in adherence (measured by medication refill rates) and a small but statistically 
significant reduction in systolic blood pressure (12). Despite the numerous effectiveness 
studies on mHealth, to our knowledge, only a few studies have examined the cost and cost-
effectiveness of mHealth interventions, and to date no studies have been conducted in the 
South African context (13-15).  The objectives of this study were: (1) to estimate the cost of 
providing routine hypertension care, (2) to assess the incremental cost of the effective one-
way SMS text-message intervention, and (3) to assess the cost-effectiveness of this 




Materials and Methods 
Study setting 
The study was carried out in 2016 in the context of the StAR-BP trial at Vanguard 
Community Health Centre (CHC) in Bonteheuwel, Cape Town. Vanguard CHC is a day-
clinic serving patients on an outpatient basis only. The clinic serves people of Langa and 
Bonteheuwel by providing a range of primary health services. In 2015, the clinic served 
approximately 27,000 patients monthly. A dedicated clinic for chronic diseases (including 
hypertension and diabetes) serves on average 500 patients weekly.    
Hypertension care pathway 
Vanguard CHC follows the South African standard treatment guidelines for the management 
of hypertension (16). Patients who have been diagnosed with high blood pressure are 
managed within a chronic disease service. The service is staffed by doctors and clinical nurse 
practitioners. At Vanguard CHC patients with hypertension are seen at a disease specific 
clinic which runs two days a week (one of these days is a combined high blood pressure and 
diabetes mellitus clinic.) Patients with appointments for routine high blood pressure care 
arrive at the facility and proceed by collecting their paper-based medical record from 
reception, they are then seen by a nurse who measures their vital signs and checks the record 
for routine screening activities which may be required. Thereafter patients are seen in a 
disease specific club room either by a clinical nurse practitioner or doctor depending on the 
appointment type (annual review, medication review) and clinic-measured blood pressure on 
the day (for example patients with a blood pressure above 160/100 mmHg will be evaluated 
by a doctor and may be referred to the emergency unit.) As per the country guidelines 
controlled hypertension is defined as systolic blood pressure measurement equal to or below 
140 mmHg, with higher values considered uncontrolled. 
Individuals with hypertension may visit the facility as infrequently as four times per year (an 
annual review and medication collection, medication review and medication collection, and 
two medication collection only visits (prescriptions are valid for a maximum of six months 
and the pharmacy will dispense a maximum of three months medication at one time.) 
Uncontrolled hypertension patients generally visit the facility more than controlled patients 
for check-ups and titration of medication doses until their blood pressure is controlled. The 
main difference in the number of scheduled visits between the two groups of patients is that 
controlled hypertension patients make between two and ten pharmacy medication collection 
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visits and two clinical follow-up visits to the facility while uncontrolled hypertension patients 
may require monthly or more frequent clinical follow-up visits (may be more than 12 per 
annum) and include medication collection. Pharmacy visits are less resource intensive as 
patients only visit the pharmacy (i.e. bypass reception) to collect their medication (which may 
already have been pre-packaged and dispensed via a third-party provider), while clinical 
follow-up visits are more resource-intensive because multiple health professionals (nurse, 
doctor, and pharmacist) are involved.  
Costing Methods 
We conducted a retrospective cost analysis for patients with a diagnosis of hypertension 
treated for raised blood pressure from the health system (provider) perspective using a 
combination of the bottom-up approach and step-down costing to estimate the monthly 
outpatient cost per visit. A costing analysis from the patient perspective was conducted using 
a structured questionnaire to estimate the monthly cost per visit to access hypertension care. 
All costs from the provider perspective were collected between June 2016 and February 
2017. The patient survey was conducted between September 2016 and December 2016. 
“Both financial and economic costs were estimated. Financial costs represented the actual 
expenditure on goods and services, while economic costs valued the cost of all inputs, even if 
these were provided for free (e.g. voluntary labour) or where the price did not reflect its true 
value such as subsidized goods.” All costs were estimated in 2016 South Africa Rand. 
Costs from the provider perspective 
The objective of the provider costing was to estimate the monthly cost per outpatient visit for 
hypertension. Two different estimation approaches were used: direct medical costs of 
hypertension care, such as the cost of drugs, were estimated using the bottom-up s approach, 
while other resources were estimated using the step-down approach (i.e. capital costs and 
recurrent costs not directly related to hypertension care). 
Bottom-up costing: This method was used to estimate the direct medical costs associated to 
hypertension management at Vanguard CHC. These costs include; human resources, medical 
drugs, laboratory tests and other medical services related to hypertension care.  To identify 
and measure these costs we conducted 10 non-participatory observations on patient’s 
management at the CHC, reviewed 200 medical records and conducted five structured 
interviews with CHC staff involved in hypertension care. All human resources involved in 
hypertension management were based on the allocation of time per related activity. The 
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schedules of visits and other laboratory tests used in the cost estimation were based on the 
standard treatment guidelines (costed per protocol). Price lists were obtained from the 
Western Cape Department of Health for medical drugs, and from Vanguard CHC for 
laboratory investigations. The direct medical cost per patient was calculated by multiplying 
resource utilisation of inputs obtained from medical records and treatment guidelines by their 
respective price. 
Step-down costing: Other costs that are not directly related to the provision of hypertension 
care, including capital costs (building, equipment and furniture) and recurrent costs incurred 
by support departments (e.g. overhead costs linked to administration, cleaning and 
maintenance) were allocated to hypertension care using step-down costing(17-19). Recurrent 
costs information was obtained from the latest financial expenditure report (2015/2016) for 
Vanguard CHC. Capital cost information was obtained from an inventory list of all the 
furniture and equipment provided at Vanguard CHC. The cost per square meter office space 
was used to estimate the buildings costs. Straight-line depreciation was used to calculate the 
financial costs of capital items while annualization was used for the economic costs. Capital 
items were annualized using a discount factor of 3% to allow for depreciation and the 
opportunity cost of purchase (17). The estimated lifespan used for buildings, furniture and 
vehicles was 30 years, 10 years and 5 years, respectively (17,18).  
Departments at Vanguard CHC were divided into two categories, overhead department and 
final service departments (20). Final service departments referred to those departments that 
provide medical services directly to patients and consisted in this study of the chronic disease 
service and a category "other departments". The overhead (or support) departments do not 
provide medical services directly to patients, but are essential for the CHC to run and provide 
services such as cleaning, administration, maintenance and security (18,21,22). The 
pharmacy department is often considered an intermediate department (17) but was included 
with the overhead departments. Overhead departmental costs were allocated to the final 
service departments in a stepwise fashion. First, we allocated recurrent and capital costs to 
the various departments directly, based on their actual resource usage (20). For example, the 
cost of building was allocated directly to the various departments based on the surface area in 
square meters of these departments.   
Subsequently, costs were allocated by the overhead departments to the chronic disease clinic. 
A set of allocation keys that describe the actual resource usage to allocate the overhead costs 
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was used. For example, maintenance costs were allocated to the chronic disease unit based on 
the floor space.  A final step in this study included the allocation of costs from the chronic 
disease service to hypertension management. There was no specific department for managing 
raised blood pressure and hypertension at Vanguard CHC so we created a virtual 
hypertension department based on the time schedules at the clinic. Patients with hypertension 
use all rooms within the chronic disease clinic three days of the week, which is equivalent to 
60% of the clinic days in a week. Therefore, we assigned 60% of all costs allocated to the 
chronic disease clinic using the step-down allocation to the virtual hypertension department.  
Once all the costs had been allocated to the virtual hypertension department, the total cost 
was divided by the total number of hypertension visits to obtain the monthly unit cost per 
outpatient visit. However, as information on hypertension visits for the year 2015 was not 
available, the total number of visits at the facility was utilised. This figure was not 
disaggregated by type of care received. The latest detailed information on hypertension at 
Vanguard CHC was from 2011, where 6% of total visits were related to hypertension care. 
We applied this percentage of hypertension visits for 2011 to estimate the total number of 
hypertension visits for the year 2015.  
Costs from the patient perspective 
We conducted a patient exit survey to obtain information on direct (medical and non-
medical) and indirect costs of hypertension from the patient perspective. Direct costs 
consisted of out-of-pocket expenditure on medical inputs (consultation, drugs and laboratory 
tests) and non-medical inputs such as food costs and costs for transportation to and from the 
health facility. Indirect costs incurred by the patient and informal caregivers were estimated 
using the human capital method, where we valued the loss of income to patients per hour 
spent away from an economically productive activity. The questionnaire also collected 
information on demographics, health-seeking behaviour, medical services received at 
Vanguard CHC, socio-economic status, and impact of disease (i.e. sex, income, transport 
costs and food costs). Income was measured by asking questions about monthly wages and 
income from various other sources (e.g. grants). The questionnaire was piloted on ten 
participants at Vanguard CHC prior to data collection.  
Incremental cost estimation of the StAR-BP Intervention 
We estimated the monthly incremental cost of the text-message based intervention under 
routine Vanguard CHC using the bottom-up approach.  The incremental cost per patient was 
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calculated by multiplying resource utilisation of inputs by their respective price. Incremental 
costs denoted the difference in total costs between usual care and the intervention. To identify 
and measure the costs of the text message intervention under routine care conditions, 
structured interviews were conducted with both Vanguard CHC staff and the StAR-BP 
intervention staff. Only costs borne by the government if the intervention was run under 
routine care at Vanguard CHC were considered. Costs included in the analysis were: human 
resources, furniture and equipment, short messaging service costs, internet costs, and other 
operational costs related to the text message based intervention in managing hypertension 
care at Vanguard CHC. The salaries for human resources used in the intervention cost 
estimation were based on the governments average pay scale, the cost of SMS and internet 
usage were based on the average 2016 rates for the top three mobile and internet providers in 
South Africa (Vodacom, MTN and Cell-C).   
Cost-effectiveness of StAR-BP Intervention 
For the effectiveness information, the results of the StAR-BP trial were used to estimate the 
incremental cost effectiveness of the text message based intervention (12). The cost data and 
the StAR-BP interventions main outcome; blood pressure reduction (expressed in mm HG) 
were combined to estimate the cost-effectiveness of the intervention. The incremental cost 
effectiveness ratio was estimated by calculating the difference in costs between the usual care 
and the intervention divided by the difference in outcome (average blood pressure over 
twelve months) between the usual care and the intervention. 
𝐼𝐶𝐸𝑅 =
𝐶𝑜𝑠𝑡𝑠 𝑜𝑓 𝑆𝑡𝐴𝑅 − 𝐵𝑃 ∗ −𝐶𝑜𝑠𝑡𝑠 𝑖𝑛 𝑢𝑠𝑢𝑎𝑙 𝑐𝑎𝑟𝑒




Data was double entered into Epi-Data software and analyzed using STATA (version 12, 
Texas: StataCorp) and Microsoft Excel®. Continuous variables were analyzed using means 
or medians and standard deviations or interquartile range, while categorical variables were 
analyzed using proportions.  
Sensitivity Analysis 
To examine how changes in the value of input variables affected the cost outcomes, we 
carried out a series of one-way deterministic sensitivity analyses. One-way sensitivity 
analysis was applied to the following variables: the discount rate for costs was varied from 
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0% to 10%, with the upper range corresponding to the maximum discount rate sometimes 
used in cost-effectiveness studies for South Africa. The utilisation rate at the facility was 
varied from 50% to a 100%. The average utilisation rate that is sometimes used in cost 
effectiveness studies for South Africa is 80%. For all other input variables (number of text 
messages and average blood pressure reduction, the baseline value was varied by 50 % in 
each direction. 
Ethics Approval  
 
Prior to commencement of the study, written informed consent was obtained from the 
participants (health workers and the patients). Anonymity was maintained throughout the 
medical records review process and we did not collect any patient identifying information 
(i.e. names and identity number). Ethics approval for this study was obtained from the 
University of Cape Town Human Research Ethics Committee (UCT_HREC: 418/2011) and 




Costs from the provider perspective  
Current management of hypertension 
Table 1 shows a summary of hypertension costs by the three perspectives of the analysis 
(health system, patient and societal). The total financial cost of hypertension management per 
patient visit at Vanguard CHC was R262, while the economic cost was similar at R263. This 
total cost includes the (non-medical) cost per outpatient visit estimated through the step-down 
costing, and the direct medical cost per visit from the bottom-up costing. The majority of the 
total cost per visit consisted of direct medical costs on drugs, laboratory investigations and 
medical staff (R228); the other costs per outpatient visits were R35. Drug costs alone 
contributed 54% (R140) of the direct medical costs while laboratory tests contributed 2% 
(R6).  
Table 1: Summary of Unit Costs from the different Perspectives 
Perspective (Usual care) Health System Patient Societal 
Type of Costs Financial Economic - Economic 
 (a) (b) (c) (e)=(b)+(c) 
Unit cost per outpatient visit 34.43 35.06  35.06 
Medical cost per outpatient visit 227.69 227.69  227.69 
Food Costs at facility   37.20 37.20 
Travel costs   11.44 11.44 
Productivity loss   122.88 122.88 
     
Total Unit Cost per visit (ZAR) 262.12 262.75 171.52 434.27 
 
Costs from the patient perspective 
Demographic and socio-economic background of study participants 
Demographic and socioeconomic characteristics of the study respondents are presented in 
table 2. A total of 246 patient exit interviews were conducted; four patients declined to 
participate. Of the 246 patients, 139 were diagnosed with hypertension with no co-
morbidities (HPT) while the other 107 were diagnosed with hypertension together with 
another comorbidity (HPT+Co). The average age or the respondents was 59 years and most 
of the respondents were women (74%).  About 34% of the respondents reported having either 
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a full-time or part-time job; the majority (62%) reported social grants as their source of 
income. Ninety-one percent of respondents reported visiting the facility in the previous 
month. The medication dispensed to participants lasted for a month for the majority (80%), 
while the other 20% used the dispensed medication for longer, indicating incomplete 
adherence.  








Mean Age (Years) 57 54 59 
Mean Income (ZAR) 
     Working 














     Male 








     Black 
     White 
     Coloured 














     No formal education 
    Primary education 
     Secondary education 














     Working full time job 
     Working part time job 
     Social Grant 













Mode of Transport 
      Bus/taxi 
      Car 
      Walking 
17.55% 








Missed a dose last month 
      Yes 







Reason for not missing a dose 
      Alarm reminders 
      Family 
      Feeling Sick 
      I just knew/remembered 
















Took alternative treatment3 
     Yes 









1 Individuals with hypertension combined with those that have hypertension & a comorbidity 
2 Refers to those unemployed, retired or disabled 
3 Alternative treatment here refers to anything else that the patients took to manage hypertension i.e. 
vitamins or herbs from the traditional healer. 
 
Direct and Indirect costs 
The costs from the patient perspective were analysed separately for patients with HPT and 
HPT+Co (see tables 3 and 4). A summary of total patients’ costs for both groups combined is 
presented in table 1. The average patient cost of HPT was R172 per month (see table 1). This 
cost consisted of direct non-medical costs (food and transportation) and indirect costs. None 
of the patients reported direct medical costs (e.g. drug costs). User fees for primary care were 
abolished in South Africa in 1994 and 1996. (23). Food costs and travel costs were modest 
since most of the people walked to the facility (67%) and did not buy any food at the facility 
(82%).  Table 4 provides an overview of direct non-medical costs by type of patient (HPT 
and HPT+Co). Transport costs (one-way) were slightly higher for HPT patients compared to 
HPT+Co patients (R37 for HPT and R34 for HPT+Co).  
 




































HPT3          
   Working 43 16.72 41 187 9 3.89 233.4 453.84 169.13 
   Not 
working 
96 18.11 84 156 13 6.69 401.4 593.62 94.26 
   All HPT 139 17.68 125 169 22 5.55 333.0 537.36 122.88 
HPT+Co4          
   Working 22 18.18 14 190 7 4.85 291.0 517.36 240.67 
   Not 
working 
85 22.52 59 164 14 3.42 205.2 414.24 68.6 
    All 107 21.63 73 168 21 3.90 234 445.26 
 
105.42 
1 “2” refers to the two-way transport cost (to and from the facility)  
2 Average salary is calculated per minute assuming an individual works 9600 minutes a month 
3 HPT represents patients with hypertension only 





The costs for food bought by patients while at the facility were also similar between the two 
groups of patients (about R11 for both). The average time spent at the facility was similar 
between HPT and HPT+Co patients (169mins and 168mins, respectively). The travel time 
from home to the facility and back was 33 min for HPT and 43 minutes for HPT+Co. In 
some cases, participants reported having a very high blood pressure reading at the facility and 
had to stay for a couple of hours while being monitored. Total time spent at the facility was 
higher for working patients compared to non-working patients. Total time consisted of travel 
time and time spent at the facility.  Indirect costs (i.e. loss of productivity) accounted for 71% 
of the patient cost. In both groups, participants who were working had a higher average direct 
non-medical and indirect cost compared to those not working or receiving social grants. The 
average productivity losses for HPT were higher than those of the HPT+Co patients (R123 
and R105 respectively) (see table 4). 
 
Table 4: Monthly Direct costs for people with hypertension (all costs in 2016 ZAR) 




n Mean (SD) Min Max n Mean (SD) Min Max 
Direct non-medical costs           
     Food Costs  
             Working 
             Not Working 









































     Transport Cost  
             Working 
             Not Working 









































           
Summary of direct non-
medical costs  
             Working 
             Not Working 
















Costs from the societal perspective  
Given the negligible difference between financial and economic costs, we used only 
economic costs in the in the estimation of total costs from the societal perspective. The 
societal costs include all costs, irrespective of who bears the costs and who receives the 
benefits in this case combining patient and provider costs. We found the monthly cost of 
hypertension from a societal perspective to be R437. Of the total cost per visit from the 
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societal perspective, costs from the provider perspective represented 61%, while patient costs 
represented 39%. The largest cost category was the direct medical costs (53%) followed by 
indirect costs (28%) and overhead costs were the smallest cost category (8%). Table 1 shows 
a summary of HPT costs from the different perspectives.  
 
Incremental costs and cost-effectiveness of StAR-BP  intervention 
 
Table 5 shows the monthly incremental cost per patient and the ICER for the text message 
intervention under routine care at Vanguard CHC. It would cost the hypertension service an 
additional R4 to add low frequency text message adherence support to the current package of 
care. With a yearly cost of R49, the ICER of the intervention is R22 per mm HG reduction at 
Vanguard CHC. 
 
Table 5 Incremental costs and ICERs for text message intervention under routine care in 2016 
ZAR 
Monthly incremental cost per participant (ZAR)1 4.06 
Yearly incremental cost per participant (ZAR) 48.72 
Average mm HG reduction in StAR-BP intervention over 12 months 2.22 
Cost per mm Hg reduction (ICER)3 21.95 
1ZAR= South African Rand 
2 Bobrow, K., Farmer, A.J., Springer, D., Shanyinde, M., Yu, L.M., Brennan, T., Rayner, B., Namane, M., Steyn, 
K., Tarassenko, L. & Levitt, N. 2016, "Mobile Phone Text Messages to Support Treatment Adherence in Adults 
with High Blood Pressure (StAR-BP): A Single-Blind, Randomized Trial", Circulation,  





One-way Univariate Sensitivity Analysis  
Figure 1: One-way univariate sensitivity analyses results. 
 
 
Figure 1 shows the impact of varying the different inputs on the incremental cost as well as to 
the total unit cost from the provider perspective. The total unit cost in the usual care arm was 
sensitive to the discount rate and utilization capacity, which was varied between 50% and 
100%. As the capacity increased, the total unit cost decreased. The effect of discount rate was 
directly proportional to the total unit cost.  We also varied the number of staff involved in the 
StAR-BP intervention and the total number of text messages sent to estimate the effect on the 
incremental costs. The incremental costs were sensitive to both the number of staff and the 




 This is the first study estimating the cost of HPT management in South Africa. Results of the 
study show that hypertension costs R434 per patient per month in an outpatient primary care 
setting in South Africa. The average cost per patient of medication alone was R140, which is 
comparable to other studies that reviewed the average cost of anti-hypertensive drugs (20-
22). 
Adding the text messaging-based intervention to usual care leads to an incremental 
cost of R4 per visit. The StAR-BP study saw a 2.2 mmHg reduction in blood pressure over a 
12-month period (12). Our cost effectiveness analysis shows that it would cost R22 for every 
mm Hg reduction in blood pressure. Based on the literature, in people aged over 50, the risk 
of strokes, CVDs and other hypertension related non-communicable diseases (NCDs) doubles 
for every 20/10 mmHg increase in blood pressure above 140/90 mmHg (24). Thus, any 
reduction in blood pressure is important. To put this 2 mm Hg reduction in context, Watkins 
et al (2016) estimated the cost-effectiveness of a salt reduction policy in South Africa; this 
policy was anticipated to reduce population systolic blood pressure in South Africa by 
slightly more than 2 mmHg on average and result in about 5600 fewer deaths and 23,000 
fewer cases of CVDs annually, or about 11% of total deaths (25). Furthermore, uncontrolled 
hypertension may lead to even more severe and debilitating sequelae over time, and thus 
higher mortality and morbidity rates. One study showed that almost 50% of all coronary heart 
diseases and strokes are as a result of uncontrolled hypertension (26). A previous study in 
South Africa estimated that 50% of stroke, 42% of ischaemic heart disease, 72% of 
hypertensive heart disease, and 22% of other CVD in adults is attributable to high blood 
pressure” (27). Thus, adequate control of hypertension, including measures to improve 
medication adherence, should be focused on in public sector primary care.  
At the same time, the cost of maintaining an mHealth intervention at scale in South 
Africa would be significant. Extrapolating the R50 incremental cost per patient per year 
would imply an annual additional investment by the national Department of Health of 
approximately R560 million or 0.3% of current public-sector expenditure (28). While this 
figure appears modest, health expenditure in South Africa has been increasing about 4% per 
year on average since 1995, though it has flattened out more recently. These trends suggest 
that mHealth for hypertension will need to provide very good value for money at scale in 
order to justify any investments on the order of one rand out of every additional ten rand 
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spent by the public health sector. In order to provide the Department of Health with better 
information for resource allocation, future work in this area will seek to (a) estimate the long-
run cost of operating the mHealth intervention at a national scale and (b) estimate reductions 
in long-run health outcomes such as averted death and disability from stroke and heart failure 
In terms of the transport and food costs of HPT and HPT+Co patients, we observed 
only a small difference between these two groups of patients. This is because we measured 
these costs based on each visit and it is not unreasonable that both groups of participants use 
the same transport systems or buy the same type of food while seeking care at the facility. 
Considering the number of times that both groups of participants visit the health facility in a 
year, we would expect the yearly total costs for transport and food to be different. The 
HPT+Co group utilised the facility more than the HPT group. Ninety-four percent of HPT 
participants reported visiting the health facility every month compared to 90% among the 
HPT+Co participants, with the other HPT and HPT+Co patients reporting visiting the facility 
every 2-3 months. Furthermore, 18% HPT+Co patients reported not taking at least one dose 
in the previous month compared to 6% in the HPT group.  
The study was context specific and based on clinical trial conducted at a single health 
care setting using intermediary outcomes, as such the study had a number of limitations. The 
results are not generalizable as we used natural units making it difficult to compare the results 
across different diseases. Due to the limited availability of detailed utilisation statistics and 
medical records as well as information by type of hypertensive patient (i.e. controlled versus 
uncontrolled), our analysis estimated the costs for an "average" hypertension patient 
combining controlled and uncontrolled. It is therefore likely that the cost has been 
overestimated for controlled patients and underestimated for uncontrolled patients. Utility 
data pertaining to electricity and water usage was only available at an aggregate level as it is 
managed by the district as it was not possible to accurately allocate retrieve utilisation at the 
facility level these costs were excluded in the cost estimations. However, in our study, the 
outpatient unit cost accounted for 13% of the total cost for hypertension per month from the 
health system perspective. To estimate the productivity losses in the patient perspective, we 
used the human approach for both the working participants and the not-working participants. 
Average hourly rates were used in both groups, however social grant was used to calculate 
the hourly rate in the not working group. The study was based on one facility nor did we 
know the total number of patients in the province making it difficult to assess whether the 
intervention was affordable in the Western Cape. Our cost estimations for the StAR*-BP 
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intervention under routine care represent a crude cost estimation that may either be 
overestimated or underestimated. 
The Western Cape Government recognises that the use of mHealth technologies may 
be beneficial and included mHealth as part of its 2030 vision for wellness plan (29). In some 
circumstances mHealth can become the “human face” of the medical staff to patients, 
improving both patient adherence and motivation. A study that made use of a 
telecommunication technology showed an improvement in adherence, reduced the number of 
visits at facilities and people were generally happy with the new system (30). A further 
inquiry to see (1) how the intervention might be modified to different 
provinces/ethnicities/languages and (2) what investments would be needed to operate at scale 






This study provides two novel contributions to the scientific literature. It is the first estimate of the 
societal cost of hypertension management in an urban South African environment. Second, it 
demonstrates that a text messaging based intervention to improve hypertension treatment adherence in 
South Africa can provide good value for money at an incremental cost R49 per patient per year and an 
incremental cost effectiveness of R22 per mmHg reduction in systolic blood pressure. Importantly, 
the next phase of this research will need to incorporate long-term cardiovascular outcomes as well as 
estimates of economies of scale and scope that may be realised by rollout of this intervention 
nationally and, potentially, integrating it with other mHealth initiatives. Our findings support ongoing 
efforts by the Department of Health to study and invest in mHealth solutions that can improve patient 
adherence and quality of care. Given the importance of hypertension as a risk factor for premature 
death and disability among South African adults, there is urgent need for research to on mHealth for 
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Part D: Policy Brief 
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INTRODUCTION 
Hypertension complications account for 9.4 
million deaths globally (Lim et al. 2013). A 
study comparing 6 countries using data 
collected between 2007 and 2010 showed that 
the prevalence of hypertension amongst adults 
aged 50 years and more was highest in South 
Africa at 78% (Lloyd-Sherlock et al. 2014). 
With hypertension causing 50% of strokes, 
heart diseases and heart failure), the disease is 
an important public health problem in the 
country (The South African Hypertension 
Society 2015).  
Nearly 50% of all hypertension patients either 
partially adhere to their medication or not at 
all, this reduces the success rate of controlling 
hypertension. Novel approaches to better 
manage hypertension and improve patient 
adherence such as mobile health (mHealth) are 
becoming increasingly popular. A recent 
community randomized trial (the StAR* trial) 
which investigated the effect of adherence 
support via SMS on treatment adherence and 
patient outcomes for the management of 
hypertension showed an improvement in 
adherence (measured by medication refill 
rates) and a small reduction in systolic blood 
pressure (Bobrow et al. 2016).   
This policy brief reports on the findings from a 
costing and cost-effectiveness study that was 
conducted at Vanguard Community Health 
Centre (Bonteheuwel, Cape Town). The study 
estimated the cost of providing routine 
hypertension care and hypertension care in the 
context of the StAR* trial from the 
government and patient’s perspective as well 
as the cost-effectiveness of the StAR* trial 
intervention.
Key Points 
1. Hypertension has a high economic
burden to the patient (28% out of
pocket non-medical costs) and is linked
to more costly conditions.
2. Drug costs are the major cost driver for
hypertension costs from the provider
perspective.
3. MHealth shows a potentially low cost of
implementation.
Hypertension management and mobile technology 
(mHealth) in South Africa 
June 2017  POLICY BRIEF
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The cost and cost effectiveness of hypertension management in the Western 
Cape. 
Figure 1: Monthly percentage distribution  
of Hypertension Costs per person: Provider perspective 
*Human resources here refer to staff directly incontact
with hypertension patients and were not included in the 
overhead costs calculation. 
The costing study at Vanguard CHC was 
carried out between August 2016 and January 
2017. The annual cost per patient to the 
government of providing hypertension care 
attending Vanguard Community Health Centre 
was R3144, or R262 per month. The cost 
elements considered include: overhead costs 
(i.e. building costs, maintenance costs and 
operational costs) and the medical costs (i.e. 
drug costs). The major cost driver being the 
drug costs, contributing 53% (R140) of the 
total cost as shown in Figure 1. 
 Despite hypertension care being provided for 
free at public health facilities, patients still 
bear costs of accessing the health facilities. To 
estimate the patient costs, we interviewed 250 
patients at the facility. The annual cost of 
seeking hypertension care per person at 
Vanguard Community Health Centre was 
R2064, or R172 per month. Patients did not 
experience direct medical costs such as drug 
costs since the government of South Africa 
provides hypertension care free of charge at 
the facility. Patients only experienced direct 
non-medical costs (i.e. transport costs and 
food costs) and indirect costs (i.e. productivity 
losses) as shown in Figure 2. The direct non-
medical out of pocket accounted for 29% of
the total patient cost. The waiting time at the 
facility resulted in the high productivity losses. 
Hypertension patients spend on average 168 
minutes waiting for a service at the facility.  
From the social perspective, the total annual 
cost of hypertension was R5208 or R434 per 
month.  Figure 3 shows the percentage 
distribution of hypertension costs from a 
societal perspective. Drug costs contributed 
32% of the total costs and travel costs were the 
least contributor at 3%. Thirty eight percent of 
the societal cost was borne by the patient 
alone.  
Figure 2: Monthly Hypertension Costs per 
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Figure 3: Monthly cost of hypertension per patient from the societal perspective (including 
government and patient costs) 
    
Mobile Health in Hypertension 
Management. 
The monthly total cost of mHealth with usual 
health is R266.81 compared to R262.75 
without the intervention as indicated in figure 
4. The difference in cost between the two is 
marginal 1.4%(R4). Based on the effectiveness 
data from the StAR* trial (Bobrow et al. 
2016), the text messaging based intervention 
showed an incremental cost effectiveness ratio 
(ICER) of R24 per mm Hg. This implies that 
for each unit reduction in blood pressure, it 
would cost the government R24 per patient if 
this messaging system is introduced under 
routine hypertension care.  With hypertension, 
the risk of developing more debilitating and 
costly conditions such as strokes and cardiac 
infarctions increases with an increase in blood 
pressure so any small reduction in blood 
pressure is important (Yusuf et al. 2004). For 
example, Watkins et al. (2016) estimated that 
a reduction of systolic blood pressure in the 
population of about 2 mmHg would result in 
5600 fewer deaths and 23,000 fewer cases of 
CVDs annually.  
Figure 4: The monthly cost of using mHealth in 
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Policy recommendations 
To improve the effectiveness of hypertension management, the following policy interventions ought to be 
considered: 
• Since the Economic Burden of hypertension is a major issue in the country:
o The government needs to develop policies to support patients that experience direct non-medical
costs such as food costs and transport costs while seeking hypertension care.
o The government to target waiting time of patients in the public health facilities in-order to
reduce productivity losses.
• The government provides hypertension drugs for free, yet they are the major cost driver:
o It may be worthwhile to implement strategies that target the risk factors of hypertension to
reduce its incidence. This will in future reduce the need for hypertension medications which will
reduce economic burden on the health system.
• Given the marginal difference in the cost of introducing mHealth (compared to the usual care) and
effectiveness of the mobile intervention shown, it would be of great value to conduct larger
demonstration projects using mHealth at population level to improve adherence as well as management.
Conclusion 
Hypertension management is not cheap, both 
to the patient and the provider (the 
government). Non-compliance to medication 
by hypertensive patients potentially drives 
these costs even higher since uncontrolled 
hypertension is linked to even more costly 
conditions (i.e. strokes). The use of an 
mHealth intervention to improve hypertension 
outcomes was found to be of low cost. A 
further inquiry to see (1) how the intervention 
might be modified to different 
provinces/ethnicities/languages and (2) what 
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Appendix A: Summary of Hypertension Costing Articles 




Perspective Hypertension costs 
(Ganiyu, Suleiman 
2014) 
Nigeria Cross sectional study 
• Case Notes 
• Direct (drug 
costs) 
 Average monthly cost per: 
• Diuretics= NGN858.6 ($5.51)  
• Blockers a= NGN1101.1 
($7.07)  
• Fixed dose combinations = 
NGN10 425. ($66.93). 
(Maetzel et al. 
2004) 
Canada • Questionnaire 






Annual cost US$3900 








Mean unit cost of illness $9393.3 
(Costa, Juvenal 
Soares Dias da et 
al. 2002) 














• Secondary data 
•  
• Direct 
 Total incremental annual direct  
 Expenditure= $US 54.0 billion  
Mean incremental annual direct 
expenditures per individual = $US 
1,131. 
 
(Nguyen et al. 
2014) 
Vietnam Retrospective survey 
• Financial records 
• Direct 
 
• Provider Median total direct costs per 
patient = US$65 
(Dib, Riera & Brazil  • Direct  Estimated direct annual cost in: 
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Perspective Hypertension costs 
Ferraz 2010) Public health system= US$ 398.9 
million 
Private health system =US$ 272.7  
(Ilesanmi, Ige & 
Adebiyi 2013) 
Nigeria Cross-sectional survey 
• Chat Review 
 
• Direct (drug 
costs) 
• Indirect 
• Patient Mean cost of treatment $9.6 
Median monthly drug cost $6 
(Al-Efan 2009) Malaysia Prevalence-based and 
incidence-based cross-sectional 
study. 






Patient The total costs for pre-
hypertensive, stage 1 and stage 2 
• Direct costs:  RM1612.38, 
RM1741.85 and 
RM2718.21   
• Indirect: RM8078.70, 
RM6654.52 and 
RM7511.41 




 • Direct (drug 
costs) 
Provider Monthly cost of hypertension  
• Serbia = 12.56 Euro  
• Bulgaria= 8.23 Euro  
Monthly cost for complicated 
hypertension  
• Serbia 13.39 Euro  






Appendix B: Consent form 
                                                  
Patient Exit Survey 
Title of Research Project: The cost and cost-effectiveness of a text-messaging based 
intervention to support people with hypertension 
Before we start with the interview, we want to make sure you understand the following 
information about the study: 
- Your participation in this study is voluntary. 
- There will be no reimbursement for participation to the study 
- You may stop the interview at any time, or you can refuse to answer individual questions. 
However, we hope that you will participate fully in this survey since the information you 
provide us is important. 
- The survey will take approximately 30minutes to complete. 
- The survey may bring some minor psychological discomfort to the respondent. The 
survey questions the respondent on sensitive issues related to their income and the income 
of the household i.e. Questions asking how much you earn, how much you use to get to 
the facility and whether you borrowed money (or sold some personal assets) to cover 
hypertension costs) 
- The information you provide will be kept strictly confidential. The consent form will be 
detached and kept separately from the questionnaire. 
- The data will be used for research purposes; your responses in the survey will not be 
linked to your identity in anyway. The completed survey and the consent form will be 
kept in a locked cabinet and only the research team will have access to the locked filing 
cabinet; electronic data will be password protected and only accessible to the members of 
the research team. 
- Do you have any questions regarding this study? Answer any questions. 
- Do you agree to participate in this study?  
 
 
WRITTEN CONSENT: I give my permission to be interviewed 
Name of the participant:     
 









Appendix C: Information Sheet 
Project Title: The cost and cost-effectiveness of a text-messaging based intervention to 
support people with hypertension 
Who we are 
Hello, my name is , and I am a member of a research team from the Health 
Economics Unit, School of Public Health and Family Medicine, University of Cape Town. 
What we are doing 
We are collecting information for a project entitled: The cost and cost-effectiveness of a 
text-messaging based intervention to support people with hypertension. In South Africa, 
hypertension is the most common reason why people visit health care facilities. It is also a 
risk factor for other diseases that cause a relatively large number of deaths in the country. To 
understand hypertension care in South Africa, we want to assess the cost of care for 
hypertension. This information will be used in other studies that aim to improve hypertension 
care in the country. 
Your Participation 
We are contacting you because of your knowledge as a patient with hypertension. We are 
asking you whether or not you will be willing to participate in the research project that 
examines the cost of accessing care for hypertension. We would like to ask you some 
questions about the services you received at this health facility for hypertension care, the 
costs you incurred while seeking care, your income and any income losses you may have 
incurred as a result of your condition. Additionally, we would like to review your medical 
record and retrieve information regarding your hypertension care and other related 
conditions. Such information includes; when, how and where you got diagnosed, the 
diagnostic tests done, the laboratory tests, the blood-pressure tests, the drugs that you take, 
how often you take each drug, the departments that you consult per clinic visit, how often you 
consult the clinic and demographic characteristics.  
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Confidentiality and consent 
Your participation is completely voluntary; you are not obliged to participate. A consent form 
will be given to you to ask whether you agree to partake in the survey and whether you agree 
to the review of your medical record. The consent forms will be stored separately in a secure 
location accessible only to the research team. If you do agree you may refuse to answer 
individual questions or stop the interview at any time. Of course, we hope that you will 
participate fully in this survey since your views are important. Similarly, the completed 
survey form as well as the data extraction form used in the review of the medical record will 
only be accessible to the research team and kept in a secure location. Electronic data will be 
password protected and only accessible to members of the research team. To preserve 
confidentiality, your name or other personal identifiers will not be used in reports of the 
findings of the research or discussed with any health care workers at this facility or 
elsewhere. 
Who to contact if you have been harmed or have any concerns  
This research has been approved by the University of Cape Town Human Research Ethics 
Committee (+27 21 406 6338). Additionally, we obtained approval from the Province. If you 
have any complaints about ethical aspects of the research or feel that you have been harmed 
in any way by participating in this study, please contact the project leader:  
Dr Olufunke Alaba 
Telephone number                             +27214066576 










Appendix D: Provider Interview Questionnaire 
Vanguard Community Health Centre 
 
Section A:  Identification 
A1 Questionnaire number    
A2 Name of Interviewer  
A3 Date of interview 
(dd/mm/yyyy) 
 
__ __/__ __/__ __ __ __ 
A4 Interview start time __ __ : __ __ 



















Section B: Questions on Hypertension management at the facility. 
Diagnosis process 
How are patients with hypertension diagnosed at the facility? Are there guidelines on how to 
diagnose hypertension?  
Who diagnoses them? What tools or equipment are used during the process of diagnosis? 
From time of arrival at the facility, what processes do patients that have been diagnosed with 
hypertension follow? 
Which departments do they go to? 
Management or treatment of hypertension 
How are patients with hypertension managed at the facility? Are there treatment guidelines 
for hypertension? How is it decided what medication or treatment regimen a patient is to be 
initiated on? 
How many days’ supply of medication do they get? 
How often do the patients visit the facility for reasons linked to their condition 
(hypertension)?  
Services Offered 
What services are available for patients with hypertension? 
Who provides what services?  
Which department do you work in? 
 What is your role in managing patients with hypertension? 
What services do you offer patients with hypertension in your department? 
Service Delivery 
How long does it take to serve one patient in your department? 
From time of arrival, how long does it take for one patient to be seen by a health provider? 
How many patients with hypertension are seen per day or hour? 
How long does it take to take the blood pressure? 
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How long does it take to collect medication at the pharmacy? 
Questions related to the StAR trial interventions 
Activities  
What activities were carried out in the StAR* study?  
Can you explain how the SMS intervention worked? 
Were there any guidelines for using the SMS intervention?  
Which departments were involved? 
How was it different from the normal standard of care? 
Were you involved in the StAR* study? 
What was your role in the study? 
How many people were involved in each activity? 
Who else was involved in the StAR* study? 
Times 
How long did it take for each activity i.e. sending SMS? 
How many times did you send messages to individuals per day? 
Did you have a specific day to send the SMS?  
How long did you spend per patient with hypertension? 
Challenges 
Were there any challenges in using the SMS intervention?  





Appendix E: Patient Exit Survey 
Vanguard Community Health Centre 
 
Introduction to the patient: 
My name is __________________________________. I work for the University of Cape 
Town and we are interested in the costs that people face when they are seeking health care. 
Hypertension being a chronic disease that is known to be the most common reason why 
people visit health facilities in South Africa, this questionnaire seeks to collect information on 
the costs that are incurred by people with hypertension. This information will be used in other 
studies that aim to improve hypertension care in the country.  
 
A1.1 Patient questionnaire number    
 
A1.2 Name of Interviewer  
A1.3 Date of interview 
(dd/mm/yyyy) 
 
__ __/__ __/__ __ __ __ 
A1.4 Interview start time __ __ : __ __ 
 
A1.5 Do you want to participate to the survey 1 Yes     GO to next section 
2 No      
A1.6 Reason for not participating 1. Language not good enough 
2. Time constraint 
3. Not comfortable 
4. Unspecified 
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SECTION A: PATIENT INFORMATION 
A2.1 Sex 1 Male 
2 Female 
A2.2 What is your date of 
birth? 
 _ __/__ __/__ __ __ __ (day/month/year) 
A2.3 Race 1. Black African
2. White
3. Indian or Asian
4. Coloured
5. Other (specify)______________________
A2.4 Marital Status 1 Married 
2  Living with partner 
3  Single/never married 
4  Widow/widower 
5  Separated 
6   Divorced 
88 Other, specify 
_________________ 
A2.5 Date of First Diagnosis __ __/__ __/__ __ __ __ 
A2.6 Date of first treatment __ __/__ __/__ __ __ __ 
A2.7 How was the patient 
diagnosed? 
1 Routine screening in clinic 
2 Routine screening in community (e.g. mobile unit, 
health fair) 
3 Having symptoms (e.g., headache) 
4 Diagnosed while in clinic or hospital for some other 
problem 
Other (explain): ___________________ 




5 Rheumatoid Arthritis 
6 Ulcerative Colitis 
7 Hypothyroidism 
8 Chronic obstructive pulmonary disorder 
9 Schizophrenia 
10 Chronic renal disease 
11 Glaucoma 
12 Coronary artery disease 
13 HIV 
14 None 
88 Other? (specify) 
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Note down the current medication regime of the patient 
 A2.9.1 Name A1.9.2 Dosage/strength A1.9.3 Frequency 
a    
b    
c    
d    
e    
 
SECTION B: HEALTH SEEKING BEHAVIOUR 
 
No Question Code 
B1 Are you visiting this facility for the first 
time for hypertension? 
1. Yes           
2. No             -> GO TO B3 







4 Faith Healer 
5 Pharmacy 
6 Health Shop 
88  Other (Specify) 
________________ 
B3 Why did you choose this health facility 
TODAY for your hypertension care? 
1   Location close to home 
2 Trust in providers/ high quality of 
care 
3 Availability of drugs 
4 Availability of female provider 
5 Recommendation or referral 
6     I was asked to come here 
88 Other, specify: _________ 
98 Do not know 
B4 What type of hypertension care are you 
receiving TODAY? 
 
1. Pharmacy visit 
2. Physician visit 
3. Adherence club 
4. All 
88 Other___________________ 
B5 How many times did you visit this 




B6 Did you ever have to stay long for 
observation because of Hypertension? 
1 Yes 
2 No -> GO TO SECTION C 




SECTION C: TRAVEL COSTS AND WAITING TIME 
I will now ask you some questions related to your visit TODAY. These questions are related 
to your mode of travel, how long it took you to come here, and how it affected your usual 
activities. 
No Question Code 
 
C1 How did you travel to this health facility today? 1 Public transport 




88 Other (specify) 
98 Don’t know 
C2 How many minutes did you take to get to this facility 
TODAY from your house (one-way)? 
 
__________minutes 
C3 When you came to the facility TODAY, did anyone 
accompany you here such as family or a friend? 











C5. Did they 
miss 
school/work 
because of this 
clinic visit? 
C6. How much does the 
person accompanying 
you earn per day? 
C7. How many 
hours of school 
did they miss? 
Person 1 1 Relative 
2 Friend 
3 Child 











Person 2 1 Relative 
2 Friend 
3 Child 












Person 3 1 Relative 
2 Friend 
3 Child 














C8 At what time did you arrive at this 
facility TODAY? 
__ __/__ __ Hrs                             
C9 How much did you pay to come to 





C10 If you did not have to come to this facility, 
what would you be doing TODAY? 
1 Working 
2 Relaxing at Home 
3 Working at Home 
4 Looking after Children 
5 Other? (specify) 
___________ 
C11 What are you doing after this clinic visit? 1 Going Home      Skip to Section D 
2 Going to work 
88 Other (specify)? 
____________ 
98 Don’t Know 
C12 Will you get your normal day’s wage for 
today? 
1. Yes  
2. No -> GO TO C14 
C13  Will you able to work a full day? 1 Yes     -> If YES skip to section D 
2 No 





SECTION D: TREATMENT COSTS 
I will now ask you some questions about the costs you incurred. These will include treatment 
costs, travel costs, food costs and costs to the people accompanying you, if any.  
About how much did you spend on each of the following items during TODAY’s visit (for 
all that don’t apply mark N/A) 
D1 Administration fees R______________________ 
D2 Consultation fees R______________________ 
D3 Laboratory tests R______________________ 
D4 Medication R______________________ 
D5 Under the table fees R______________________ 
 
SECTION E: FOOD AND GUARDIAN COSTS 
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No Question Code 
E1 When you came did you bring something to 
eat? 
1.  Yes 
2.  No 
E2 If No, did you buy anything to eat? 1 Yes 
2 No    -> GO TO E4 
E3 How much did you pay in total for the food?  
R_______________ 
E4 Did you get someone to look after your 
children or the house while you visited the 
clinic? (i.e. guardian or caregiver) 
1. Yes 
2. No    -> GO TO Section F 
E5 How much are you paying them? R__________________ 
 
SECTION F: MEDICATION COMPLIANCE AND ADHERENCE 
NO Question Code 
F1 
 
During the past month, did you on 
any occasion not take your blood 
pressure medication? 
1.  Yes    -> GO TO F3 
2.  No 
 
F2 If NO, what made you 
remember to take your 
medication on time? 
1.  Caregiver 
2.  Reminders (e.g. 
alarm) 
3. Adherence clubs 
4.  Family  
5. Headache 
6. Phone app 
7. Feeling sick 
8. I just knew 
88 Other (please specify) 
98 Don’t know 
F3 In the past month, did you at any 
moment feel the need to stop taking 
hypertension medication? 
1.  Yes  
2.  No        -> GO TO F5 
 
F4 Why did you feel like not 
taking the tablets? 
1.  I was feeling fine 
2.  Tired of taking 
medication. 
3. Too much medication 
4.  Side Effects 
5.  Consulting with other 
health care practices 
(e.g. traditional healers) 
88 Other (specify) 
____________________ 
98   Don’t know 
F5 Thinking back last month, did you 
take anything else other than your 
normal hypertension tablets to 
control your hypertension? E.g. 
vitamins 
1.  Yes  
2.  No 
98   Don’t know 
F6 How long will the supply of medicine that you 
received TODAY last? 
1. One Month 
2. Two Months 
3. Three Months 






F8 Are there any other costs that you incurred because 
of TODAY’S visit that I haven’t asked? 
 
1. Yes 
2.   No 
98 Don’t know 
 
Please list the costs and their respective amounts below. 
 F9 Cost F10 Amount (ZAR) 
a   
b   
c   
 
SECTION G: SOCIO-ECONOMIC INFORMATION 
G1 What is your employment status? 1.  Employed full-time 
2.  Self-employed (formal sector) 
3.  Part-time/contract/temporary 
4.  Casual 
5.  Self-employed (informal sector) 
6.  Unemployed 
7.  Housewife 
8.  Pensioner 
9.  Student/learner/child 
10.  Disabled and unable to work 
98.  Don’t know 
88        Other (specify) 
            _____________ 
G2 Is the reason for your 
unemployment your chronic 
illness (hypertension)? 
1 Yes 
2 No    
G3 If yes, when was the last time you 
were working? (month/year) 
 
G4 Are you receiving any income? 1 Yes 
2 No 
G5 What is your source of income? 1 Working at a full-time job 
2 Working at a part time job 
3 Social Grant 
4 I receive money from other people 
G6 What was your total average monthly income 
PRIOR to your diagnosis with hypertension?  
 
R__________________ 





G7 Have you ever stopped working/going to 
school/doing housework due to your hypertension? 
1 Yes 
2 No      -> GO TO   G9 
G8 If yes, for how long? 1 Less than 1 month 
2 One month 
3 2-3 months
4 4-5 months
5 More than 6 months 
G9 Do you have children? 1 Yes 
2 No       -> GO TO G11 




5 More than five 
















G12 What is your highest level of 
education? 
1 No formal education 
2 Primary education 
3 Secondary education 
4 Tertiary education 
88 Other (specify) __________ 
G13 Are you covered by a Medical 
Aid or Medical Benefit Scheme 
or any scheme that helps you pay 






SECTION H: COPING COSTS 
I will now ask you some questions about how you cover the cost of your care.  
 
 
Thank You for participating in the survey! 
 
No Question Code 
H1 Did you borrow any money when you 
came for this clinic visit? 
 
1.  Yes  
2.  No         -> GO TO H4 
 
H2 How much did you borrow? R    _______________ 
H3 Does the money have interest? 1.  Yes  
2.  No   -> GO TO H5 
H4 How much interest do you have to pay? R_____________ 
H5 Did you take up any extra work to cover 
the costs for TODAY’S visit? 
1.  Yes  
2.  No          
H6 Was there anything that you sold to cover the 
costs for TODAY’S clinic visit i.e. jewellery, 
radio, television or furniture? 
1.  Yes  
2.  No      -> GO TO H9 
H7 How much did you get from the sale? R___________________ 
H8 For TODAY’S clinic visit, did you 
withdraw any money from your savings 
account? 
1.  Yes  
2.  No                  -> GO TO H10 
H9 How much did you withdraw? R______________________ 
H10 Did you have to modify your diet due to 
Hypertension? 
1 Yes 
2 No                      




H12 How much is this diet modification 
costing you per month? 
R___________________  
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Appendix F: Observation Tool 
WAITING TIMES AND CONSULTATION TIMES 
Date: 




Unit/Section Time of arrival at 
the Unit/Section (a) 
Time of Leaving the 
Unit/section (b) 








Other Section (s) 
(1) 
(2) 
Observer’s signature _________________________ 
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Appendix G: UCT Ethics Approval letter (HREC) 
UNIVERSITY OF CAPE TOWN
Faculty of Health Sciences
Human Research Ethics Committee
Room E52-24 Old Main Building 
Groote Schuur Hospital 
Observatory 7925 
Telephone [021] 406 6338 • Facsimile [021] 406 6411 
Email: nosi.tsama@uct.ac.za 
Website: www.health.uct.ac.za/fhs/research/humanethics/forms 
07 April 2016 
14 HREC REF: 157/2016 
Dr O Alaba
Health Economics Unit 
Public Health & Family 
Medicine Falmouth 
Building 
Dear Dr Alaba 
PROJECT TITLE: THE COST AND COST-EFFECTIVENESS OF A TEXT-MESSAGING 
BASED INTERVENTION TO SUPPORT PEOPLE WITH HYPERTENSION (Masters 
candidate D Hongoro) sub-study linked to 418/2011.
Thank you for your response letter to the Faculty of Health Sciences Human 
Research Ethics Committee received on the 07 April 2016. 
It is a pleasure to inform you that the HREC has formally approved the above-mentioned 
study. 
Approval is granted for one year until 30 April 2017.
Please submit a progress form, using the standardised Annual Report Form if the 
study continues beyond the approval period. Please submit a Standard Closure form 
if the study is completed within the approval period. 
(Forms can be found on our website: 
www.health.uct.ac.za/fhs/research/humanethics/forms) 
We acknowledge that the student Dan/een Hongoro will be involved in this study. 
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Please quote the HREC REF in all your correspondence.
Please note that the ongoing ethical conduct of the study remains the responsibility 
of the principal investigator. 
Please note that for all studies approved by the HREC, the principal investigator must 
obtain appropriate institutional approval before the research may occur." 
Yours sincerely 
15 PROFESSOR M BLOCKMAN 
CHAIRPERSON. FHS HUMAN RESEARCH ETHICS COMMITTEE
Federal Wide Assurance Number: FWA00001637. 
Institutional Review Board (IRB) number: IRB00001938 
16 HREC 
157/2016 
This serves to confirm that the University of Cape Town Human Research Ethics 
Committee complies to the Ethics Standards for Clinical Research with a new drug in 
patients, based on the Medical Research Council (MRC-SA), Food and Drug 
Administration (FDA-USA), International Convention on Harmonisation Good Clinical 
Practice (ICH GCP), South African Good Clinical Practice Guidelines (DOH 2006), 
based on the Association of the British Pharmaceutical Industry Guidelines 
(ABPI),and Declaration of Helsinki (2013) guidelines. 
The Human Research Ethics Committee granting this approval is in compliance with 
the ICH Harmonised Tripartite Guidelines E6: Note for Guidance on Good Clinical 
Practice (CPMP/ICH/135/95) and FDA Code Federal Regulation Part 50, 56 and 
312.REC 157/2016
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published article is initially included in PubMed as it takes PubMed 
additional time to code this information. 
Abstract 
The Abstract of the manuscript should not exceed 350 words and must be structured into 
separate sections: Background, the context and purpose of the study; Methods, 
how the study was performed and statistical tests used; Results, the main findings; 
Conclusions, brief summary and potential implications. Please minimize the use of 
abbreviations and do not cite references in the abstract. Trial registration, if your research 
article reports the results of a controlled health care intervention, please list 
your trial registry, along with the unique identifying number (e.g. Trial registration: Current 
Controlled Trials ISRCTN73824458). Please note that there should be no space 
between the letters and numbers of your trial registration number. We recommend 
manuscripts that report randomized controlled trials follow the CONSORT extension for 
abstracts. 
Keywords 
Three to ten keywords representing the main content of the article. 
Background 
The Background section should be written in a way that is accessible to researchers without 
specialist knowledge in that area and must clearly state - and, if helpful, 
illustrate - the background to the research and its aims. Reports of clinical research should, 
where appropriate, include a summary of a search of the literature to indicate 
why this study was necessary and what it aimed to contribute to the field. The section should 
end with a brief statement of what is being reported in the article. 
Methods 
The methods section should include the design of the study, the setting, the type of 
participants or materials involved, a clear description of all interventions and 
comparisons, and the type of analysis used, including a power calculation if appropriate. 
Generic drug names should generally be used. When proprietary brands are used in 
research, include the brand names in parentheses in the Methods section. 
For studies involving human participants a statement detailing ethical approval and consent 
should be included in the methods section. For further details of the journal's 
editorial policies and ethical guidelines see 'About this journal'. 








Results and discussion 
Conclusions 
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Conclusions 
This should state clearly the main conclusions of the research and give a clear explanation of 
their importance and relevance. Summary illustrations may be included. 
List of abbreviations 
If abbreviations are used in the text they should be defined in the text at first use, and a list of 
abbreviations can be provided, which should precede the competing interests 
and authors' contributions. 
Competing interests 
A competing interest exists when your interpretation of data or presentation of information 
may be influenced by your personal or financial relationship with other people or 
organizations. Authors must disclose any financial competing interests; they should also 
reveal any non-financial competing interests that may cause them embarrassment 
were they to become public after the publication of the manuscript. 
Authors are required to complete a declaration of competing interests. All competing interests 
that are declared will be listed at the end of published articles. Where an 
author gives no competing interests, the listing will read 'The author(s) declare that they have 
no competing interests'. 
When completing your declaration, please consider the following questions: 
Financial competing interests 
In the past three years have you received reimbursements, fees, funding, or salary from an 
organization that may in any way gain or lose financially from the 
publication of this manuscript, either now or in the future? Is such an organization financing 
this manuscript (including the article-processing charge)? If so, please 
specify. 
Do you hold any stocks or shares in an organization that may in any way gain or lose 
financially from the publication of this manuscript, either now or in the future? If 
so, please specify. 
Do you hold or are you currently applying for any patents relating to the content of the 
manuscript? Have you received reimbursements, fees, funding, or salary from 
an organization that holds or has applied for patents relating to the content of the manuscript? 
If so, please specify. 
Do you have any other financial competing interests? If so, please specify. 
Non-financial competing interests 
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Are there any non-financial competing interests (political, personal, religious, ideological, 
academic, intellectual, commercial or any other) to declare in relation to this 
manuscript? If so, please specify. 
If you are unsure as to whether you, or one your co-authors, has a competing interest please 
discuss it with the editorial office. 
Authors' contributions 
In order to give appropriate credit to each author of a paper, the individual contributions of 
authors to the manuscript should be specified in this section. 
According to ICMJE guidelines, An 'author' is generally considered to be someone who has 
made substantive intellectual contributions to a published study. To qualify as an 
author one should 1) have made substantial contributions to conception and design, or 
acquisition of data, or analysis and interpretation of data; 2) have been involved in 
drafting the manuscript or revising it critically for important intellectual content; 3) have 
given final approval of the version to be published; and 4) agree to be accountable 
for all aspects of the work in ensuring that questions related to the accuracy or integrity of 
any part of the work are appropriately investigated and resolved. Each author 
should have participated sufficiently in the work to take public responsibility for appropriate 
portions of the content. Acquisition of funding, collection of data, or general 
supervision of the research group, alone, does not justify authorship. 
We suggest the following kind of format (please use initials to refer to each author's 
contribution): AB carried out the molecular genetic studies, participated in the sequence 
alignment and drafted the manuscript. JY carried out the immunoassays. MT participated in 
the sequence alignment. ES participated in the design of the study and 
performed the statistical analysis. FG conceived of the study, and participated in its design 
and coordination and helped to draft the manuscript. All authors read and 
approved the final manuscript. 
All contributors who do not meet the criteria for authorship should be listed in an 
acknowledgements section. Examples of those who might be acknowledged include a 
person who provided purely technical help, writing assistance, a department chair who 
provided only general support, or those who contributed as part of a large 
collaboration group. 
Authors' information 
You may choose to use this section to include any relevant information about the author(s) 
that may aid the reader's interpretation of the article, and understand the 
standpoint of the author(s). This may include details about the authors' qualifications, current 
positions they hold at institutions or societies, or any other relevant 
background information. Please refer to authors using their initials. Note this section should 
not be used to describe any competing interests. 
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including their source(s) of funding. We suggest wording such as 'We thank Jane 
Doe who provided medical writing services on behalf of XYZ Pharmaceuticals Ltd.' 
If you would like the names of the individual members of a collaboration Group to be 
searchable through their individual PubMed records, please ensure that the title of the 
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Endnotes 
Endnotes should be designated within the text using a superscript lowercase letter and all 
notes (along with their corresponding letter) should be included in the Endnotes 
section. Please format this section in a paragraph rather than a list. 
References 
All references, including URLs, must be numbered consecutively, in square brackets, in the 
order in which they are cited in the text, followed by any in tables or legends. 
Each reference must have an individual reference number. Please avoid excessive 
referencing. If automatic numbering systems are used, the reference numbers must be 
finalized and the bibliography must be fully formatted before submission. 
Only articles, clinical trial registration records and abstracts that have been published or are 
in press, or are available through public e-print/preprint servers, may be cited; 
unpublished abstracts, unpublished data and personal communications should not be included 
in the reference list, but may be included in the text and referred to as 
"unpublished observations" or "personal communications" giving the names of the involved 
researchers. Obtaining permission to quote personal communications and 
unpublished data from the cited colleagues is the responsibility of the author. Footnotes are 
not allowed, but endnotes are permitted. Journal abbreviations follow Index 
Medicus/MEDLINE. Citations in the reference list should include all named authors, up to 
the first six before adding 'et al.'.. 
Any in press articles cited within the references and necessary for the reviewers' assessment 
of the manuscript should be made available if requested by the editorial office. 
An Endnote style file is available. 
Examples of the BMC Public Health reference style are shown below. Please ensure that the 
reference style is followed precisely; if the references are not in the correct style 
they may have to be retyped and carefully proofread. 
All web links and URLs, including links to the authors' own websites, should be given a 
reference number and included in the reference list rather than within the text of the 
manuscript. They should be provided in full, including both the title of the site and the URL, 
as well as the date the site was accessed, in the following format: The Mouse 
Tumor Biology Database. http://tumor.informatics.jax.org/mtbwi/index.do. Accessed 20 May 
2013. If an author or group of authors can clearly be associated with a web link, 
such as for weblogs, then they should be included in the reference. 
Authors may wish to make use of reference management software to ensure that reference 
lists are correctly formatted. An example of such software is Papers, which is 
part of Springer Science+Business Media. 
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Examples of the BMC Public Health reference style 
Article within a journal 
Smith JJ. The world of science. Am J Sci. 1999;36:234-5. 
Article within a journal (no page numbers) 
Rohrmann S, Overvad K, Bueno-de-Mesquita HB, Jakobsen MU, Egeberg R, Tjønneland A, 
et al. Meat consumption and mortality - results from the European Prospective 
Investigation into Cancer and Nutrition. BMC Medicine. 2013;11:63. 
Article within a journal by DOI 
Slifka MK, Whitton JL. Clinical implications of dysregulated cytokine production. Dig J Mol 
Med. 2000; doi:10.1007/s801090000086. 
Article within a journal supplement 
Frumin AM, Nussbaum J, Esposito M. Functional asplenia: demonstration of splenic activity 
by bone marrow scan. Blood 1979;59 Suppl 1:26-32. 
Book chapter, or an article within a book 
Wyllie AH, Kerr JFR, Currie AR. Cell death: the significance of apoptosis. In: Bourne GH, 
Danielli JF, Jeon KW, editors. International review of cytology. London: Academic; 
1980. p. 251-306. 
OnlineFirst chapter in a series (without a volume designation but with a DOI) 
Saito Y, Hyuga H. Rate equation approaches to amplification of enantiomeric excess and 
chiral symmetry breaking. Top Curr Chem. 2007. doi:10.1007/128_2006_108. 
Complete book, authored 
Blenkinsopp A, Paxton P. Symptoms in the pharmacy: a guide to the management of 
common illness. 3rd ed. Oxford: Blackwell Science; 1998. 
Online document 
Doe J. Title of subordinate document. In: The dictionary of substances and their effects. 
Royal Society of Chemistry. 1999. http://www.rsc.org/dose/title of subordinate 
document. Accessed 15 Jan 1999. 
Online database 
Healthwise Knowledgebase. US Pharmacopeia, Rockville. 1998. http://www.healthwise.org. 
Accessed 21 Sept 1998. 
Supplementary material/private homepage 
Doe J. Title of supplementary material. 2000. http://www.privatehomepage.com. Accessed 
22 Feb 2000. 
University site 
Doe, J: Title of preprint. http://www.uni-heidelberg.de/mydata.html (1999). Accessed 25 Dec 
1999. 
FTP site 
Doe, J: Trivial HTTP, RFC2169. ftp://ftp.isi.edu/in-notes/rfc2169.txt (1999). Accessed 12 
Nov 1999. 
Organization site 
ISSN International Centre: The ISSN register. http://www.issn.org (2006). Accessed 20 Feb 
2007. 
Dataset with persistent identifier 
Zheng L-Y, Guo X-S, He B, Sun L-J, Peng Y, Dong S-S, et al. Genome data from sweet and 
grain sorghum (Sorghum bicolor). GigaScience Database. 2011. http://dx.doi.org 
/10.5524/100012. 
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format. If a figure consists of separate parts, it is important that a single composite illustration 
file be submitted which contains all parts of the figure. There is no charge for 
the use of color figures. 
Please read our figure preparation guidelines for detailed instructions on maximising the 
quality of your figures. 
Formats 
The following file formats can be accepted: 
PDF (preferred format for diagrams) 
DOCX/DOC (single page only) 
PPTX/PPT (single slide only) 
EPS 





The legends should be included in the main manuscript text file at the end of the document, 
rather than being a part of the figure file. For each figure, the following 
information should be provided: Figure number (in sequence, using Arabic numerals - i.e. 
Figure 1, 2, 3 etc); short title of figure (maximum 15 words); detailed legend, up 
to 300 words. 
Please note that it is the responsibility of the author(s) to obtain permission from the 
copyright holder to reproduce figures or tables that have previously 
been published elsewhere. 
Preparing tables 
Each table should be numbered and cited in sequence using Arabic numerals (i.e. Table 1, 2, 
3 etc.). Tables should also have a title (above the table) that summarizes the 
whole table; it should be no longer than 15 words. Detailed legends may then follow, but they 
should be concise. Tables should always be cited in text in consecutive 
numerical order. 
Smaller tables considered to be integral to the manuscript can be pasted into the end of the 
document text file, in A4 portrait or landscape format. These will be typeset and 
displayed in the final published form of the article. Such tables should be formatted using the 
'Table object' in a word processing program to ensure that columns of data are 
kept aligned when the file is sent electronically for review; this will not always be the case if 
columns are generated by simply using tabs to separate text. Columns and rows 
of data should be made visibly distinct by ensuring that the borders of each cell display as 
black lines. Commas should not be used to indicate numerical values. Color and 
shading may not be used; parts of the table can be highlighted using symbols or bold text, the 
meaning of which should be explained in a table legend. Tables should not be 
embedded as figures or spreadsheet files. 
Larger datasets or tables too wide for a portrait page can be uploaded separately as additional 
files. Additional files will not be displayed in the final, laid-out PDF of the 
article, but a link will be provided to the files as supplied by the author. 
Tabular data provided as additional files can be uploaded as an Excel spreadsheet (.xls ) or 
comma separated values (.csv). As with all files, please use the standard file 
extensions. 
Preparing additional files 
Although BMC Public Health does not restrict the length and quantity of data included in an 
article, we encourage authors to provide datasets, tables, movies, or other 
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information as additional files. 
Please note: All Additional files will be published along with the article. Do not include files 
such as patient consent forms, certificates of language editing, or revised 
versions of the main manuscript document with tracked changes. Such files should be sent by 
email to editorial@biomedcentral.com, quoting the Manuscript ID number. 
Results that would otherwise be indicated as "data not shown" can and should be included as 
additional files. Since many weblinks and URLs rapidly become broken, BMC 
Public Health requires that supporting data are included as additional files, or deposited in a 
recognized repository. Please do not link to data on a personal/departmental 
website. The maximum file size for additional files is 20 MB each, and files will be virus-
scanned on submission. 
Additional files can be in any format, and will be downloadable from the final published 
article as supplied by the author. We recommend CSV rather than PDF for tabular 
data. 
Certain supported files formats are recognized and can be displayed to the user in the 
browser. These include most movie formats (for users with the Quicktime plugin), 
mini-websites prepared according to our guidelines, chemical structure files (MOL, PDB), 
geographic data files (KML). 
If additional material is provided, please list the following information in a separate section 
of the manuscript text: 
File name (e.g. Additional file 1) 
File format including the correct file extension for example .pdf, .xls, .txt, .pptx (including 
name and a URL of an appropriate viewer if format is unusual) 
Title of data 
Description of data 
Additional files should be named "Additional file 1" and so on and should be referenced 
explicitly by file name within the body of the article, e.g. 'An additional movie file 
shows this in more detail [see Additional file 1]'. 
Additional file formats 
Ideally, file formats for additional files should not be platform-specific, and should be 
viewable using free or widely available tools. The following are examples of suitable 
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PDF (Adode Acrobat) 
Animations 
SWF (Shockwave Flash) 
Movies 
MP4 (MPEG 4) 
MOV (Quicktime) 
Tabular data 
XLS, XLSX (Excel Spreadsheet) 
CSV (Comma separated values) 
As with figure files, files should be given the standard file extensions. 
Mini-websites 
Small self-contained websites can be submitted as additional files, in such a way that they 
will be browsable from within the full text HTML version of the article. In order to 
do this, please follow these instructions: 
Create a folder containing a starting file called index.html (or index.htm) in the root. 
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Put all files necessary for viewing the mini-website within the folder, or sub-folders. 
Ensure that all links are relative (ie "images/picture.jpg" rather than "/images/picture.jpg" or 
"http://yourdomain.net/images/picture.jpg" or "C:\Documents and 
Settings\username\My Documents\mini-website\images\picture.jpg") and no link is longer 
than 255 characters. 
Access the index.html file and browse around the mini-website, to ensure that the most 
commonly used browsers (Internet Explorer and Firefox) are able to view all 
parts of the mini-website without problems, it is ideal to check this on a different machine. 
Compress the folder into a ZIP, check the file size is under 20 MB, ensure that index.html is 
in the root of the ZIP, and that the file has .zip extension, then submit as 
an additional file with your article. 
Style and language 
General 
Currently, BMC Public Health can only accept manuscripts written in English. Spelling 
should be US English or British English, but not a mixture. 
There is no explicit limit on the length of articles submitted, but authors are encouraged to be 
concise. 
BMC Public Health will not edit submitted manuscripts for style or language; reviewers may 
advise rejection of a manuscript if it is compromised by grammatical errors. 
Authors are advised to write clearly and simply, and to have their article checked by 
colleagues before submission. In-house copyediting will be minimal. Non-native 
speakers of English may choose to make use of a copyediting service. 
Language editing 
For authors who wish to have the language in their manuscript edited by a native-English 
speaker with scientific expertise, BioMed Central recommends Edanz. BioMed 
Central has arranged a 10% discount to the fee charged to BioMed Central authors by Edanz. 
Use of an editing service is neither a requirement nor a guarantee of 
acceptance for publication. Please contact Edanz directly to make arrangements for editing, 
and for pricing and payment details. 
Help and advice on scientific writing 
The abstract is one of the most important parts of a manuscript. For guidance, please visit our 
page on Writing titles and abstracts for scientific articles. 
Tim Albert has produced for BioMed Central a list of tips for writing a scientific manuscript. 
American Scientist also provides a list of resources for science writing. For more 
detailed guidance on preparing a manuscript and writing in English, please visit the BioMed 
Central author academy. 
Abbreviations 
Abbreviations should be used as sparingly as possible. They should be defined when first 
used and a list of abbreviations can be provided following the main manuscript text. 
Typography 
Please use double line spacing. 
Type the text unjustified, without hyphenating words at line breaks. 
Use hard returns only to end headings and paragraphs, not to rearrange lines. 
Capitalize only the first word, and proper nouns, in the title. 
All lines and pages should be numbered. Authors are asked to ensure that line numbering is 
included in the main text file of their manuscript at the time of submission 
to facilitate peer-review. Once a manuscript has been accepted, line numbering should be 
removed from the manuscript before publication. For authors submitting 
their manuscript in Microsoft Word please do not insert page breaks in your manuscript to 
ensure page numbering is consistent between your text file and the PDF 
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generated from your submission and used in the review process. 
Use the BMC Public Health. 
Footnotes are not allowed, but endnotes are permitted. 
Please do not format the text in multiple columns. 
Greek and other special characters may be included. If you are unable to reproduce a 
particular special character, please type out the name of the symbol in full. 
Please ensure that all special characters used are embedded in the text, otherwise they will be 
lost during conversion to PDF. 
Units 
SI units should be used throughout (liter and molar are permitted, however). 
reference format 
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